Clinical trial results:
A Phase 2b, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Cream Applied Once or Twice Daily for 6 Weeks in Participants With Mild or Moderate Atopic Dermatitis

Summary

EudraCT number	2018-003050-24
Trial protocol	LV DE HU BG PL DK
Global end of trial date	07 May 2020

Results information

Result version number	v1
This version publication date	12 November 2020
First version publication date	12 November 2020

Trial information

Trial identification

Sponsor protocol code	B7931022

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03903822
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer Inc., Pfizer ClinicalTrials.gov Call Center, 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 September 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	07 May 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy of multiple dose levels of PF-06700841 topical cream versus vehicle, applied once daily (QD) or twice daily (BID), on percent change from baseline in eczema area and severity Index (EASI) in subjects with mild or moderate atopic dermatitis (AD).

Protection of trial subjects:

The study was conducted in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 May 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 27
Country: Number of subjects enrolled	Bulgaria: 17
Country: Number of subjects enrolled	Canada: 10
Country: Number of subjects enrolled	Denmark: 1
Country: Number of subjects enrolled	Germany: 28
Country: Number of subjects enrolled	Hungary: 9
Country: Number of subjects enrolled	Japan: 38
Country: Number of subjects enrolled	Latvia: 10
Country: Number of subjects enrolled	Poland: 11
Country: Number of subjects enrolled	United States: 141
Worldwide total number of subjects	292
EEA total number of subjects	76

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	6
Adults (18-64 years)	261
From 65 to 84 years	25
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was conducted at 77 sites in the 10 countries from 13 May 2019 to 07 May 2020. A total of 292 subjects were enrolled.

Period 1

Period 1 title	Treatment Phase (6 Weeks)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Vehicle Cream Once Daily (QD)

Arm description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received vehicle cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 0.1% Cream QD

Arm description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.1 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 0.3% Cream QD

Arm description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.3 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 1.0% Cream QD

Arm description:

Subjects or caregivers of subjects, topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 1.0 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 3.0% Cream QD

Arm description:

Subjects or caregivers of subjects, topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 3.0% cream once daily for maximum of 6 weeks.

Arm title	Vehicle Cream Twice Daily (BID)

Arm description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received vehicle cream twice daily for maximum of 6 weeks.

Arm title	PF-06700841 0.3% Cream BID

Arm description:

Subjects or caregivers of subjects topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental

Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.3% cream twice daily for maximum of 6 weeks.

Arm title	PF-06700841 1.0% Cream BID

Arm description:

Subjects or caregivers of subjects topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 1.0 % cream twice daily for maximum of 6 weeks.

Number of subjects in period 1	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD
Started	37	37	36
Completed	28	27	33
Not completed	9	10	3
Consent withdrawn by subject	2	4	2
Physician decision	-	2	-
Adverse event, non-fatal	3	3	1
Pregnancy	-	-	-
Unspecified	2	1	-
Refused Further Treatment	2	-	-
Lost to follow-up	-	-	-
Protocol deviation	-	-	-
Lack of efficacy	-	-	-

Number of subjects in period 1	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)
Started	37	36	36
Completed	32	31	25
Not completed	5	5	11
Consent withdrawn by subject	2	1	2
Physician decision	-	-	-
Adverse event, non-fatal	1	1	6
Pregnancy	1	1	-

Unspecified	-	1	1
Refused Further Treatment	-	-	1
Lost to follow-up	-	-	-
Protocol deviation	1	-	-
Lack of efficacy	-	1	1

Number of subjects in period 1	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Started	36	37
Completed	31	33
Not completed	5	4
Consent withdrawn by subject	3	3
Physician decision	-	-
Adverse event, non-fatal	1	-
Pregnancy	-	-
Unspecified	-	-
Refused Further Treatment	-	-
Lost to follow-up	1	1
Protocol deviation	-	-
Lack of efficacy	-	-

Period 2	
Period 2 title	Follow up Phase (4 Weeks)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Vehicle Cream Once Daily (QD)

Arm description:

Subjects or caregivers of subjects topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received vehicle cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 0.1% Cream QD

Arm description:

Subjects or caregivers of subjects topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.1 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 0.3% Cream QD

Arm description:

Subjects or caregivers of subjects topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.3 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 1.0% Cream QD

Arm description:

Subjects or caregivers of subjects topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 1.0 % cream once daily for maximum of 6 weeks.

Arm title	PF-06700841 3.0% Cream QD

Arm description:

Subjects or caregivers of subjects topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 3.0 % cream once daily for maximum of 6 weeks.

Arm title	Vehicle Cream Twice Daily (BID)

Arm description:

Subjects or caregivers of subjects topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received vehicle cream twice daily for maximum of 6 weeks.

Arm title	PF-06700841 0.3% Cream BID

Arm description:

Subjects or caregivers of subjects topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 0.3% cream twice daily for maximum of 6 weeks.

Arm title	PF-06700841 1.0% Cream BID

Arm description:

Subjects or caregivers of subjects topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Arm type	Experimental
Investigational medicinal product name	PF-06700841
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Subject received PF-06700841 1.0 % cream twice daily for maximum of 6 weeks.

Number of subjects in period 2	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD
Started	28	27	33
Completed	29	29	32
Not completed	8	8	4
Consent withdrawn by subject	2	5	3
Refused Further Study Procedures	-	-	-
Adverse event, non-fatal	3	2	1
Pregnancy	-	-	-

Unspecified	1	1	-
Lost to follow-up	2	-	-
Lack of efficacy	-	-	-
Joined	9	10	3
Continue to follow up	9	10	3

Number of subjects in period 2	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)
Started	32	31	25
Completed	33	32	28
Not completed	4	4	8
Consent withdrawn by subject	2	2	2
Refused Further Study Procedures	-	-	1
Adverse event, non-fatal	1	-	5
Pregnancy	1	1	-
Unspecified	-	-	-
Lost to follow-up	-	-	-
Lack of efficacy	-	1	-
Joined	5	5	11
Continue to follow up	5	5	11

Number of subjects in period 2	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Started	31	33
Completed	31	31
Not completed	5	6
Consent withdrawn by subject	3	3
Refused Further Study Procedures	-	-
Adverse event, non-fatal	1	-
Pregnancy	-	-
Unspecified	-	-
Lost to follow-up	1	3
Lack of efficacy	-	-
Joined	5	4
Continue to follow up	5	4

Baseline characteristics

Reporting groups	
Reporting group title	Vehicle Cream Once Daily (QD)
Reporting group description:	
Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.1% Cream QD
Reporting group description:	
Subjects or caregivers of subjects, topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% Cream QD
Reporting group description:	
Subjects or caregivers of subjects, topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% Cream QD
Reporting group description:	
Subjects or caregivers of subjects, topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 3.0% Cream QD
Reporting group description:	
Subjects or caregivers of subjects, topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	Vehicle Cream Twice Daily (BID)
Reporting group description:	
Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 0.3% Cream BID
Reporting group description:	
Subjects or caregivers of subjects topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	
Reporting group title	PF-06700841 1.0% Cream BID
Reporting group description:	
Subjects or caregivers of subjects topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.	

Reporting group values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD
Number of subjects	37	37	36
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0

Children (2-11 years)	0	0	0
Adolescents (12-17 years)	2	1	1
Adults (18-64 years)	31	32	31
From 65-84 years	4	4	4
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	39.1	40.8	43.4
standard deviation	± 16.80	± 15.35	± 16.43
Sex: Female, Male			
Units: Subjects			
Female	20	19	24
Male	17	18	12
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	4	8	4
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	8	7	9
White	24	22	21
More than one race	0	0	2
Unknown or Not Reported	1	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	3
Not Hispanic or Latino	37	37	32
Unknown or Not Reported	0	0	1

Reporting group values	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)
Number of subjects	37	36	36
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	1	0	1
Adults (18-64 years)	36	34	29
From 65-84 years	0	2	6
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	38.4	40.5	42.3
standard deviation	± 12.90	± 12.30	± 18.18
Sex: Female, Male			
Units: Subjects			
Female	23	15	19
Male	14	21	17

Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	8	10	9
Native Hawaiian or Other Pacific Islander	1	0	1
Black or African American	6	4	6
White	20	21	20
More than one race	2	1	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	2	1	3
Not Hispanic or Latino	35	35	33
Unknown or Not Reported	0	0	0

Reporting group values	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID	Total
Number of subjects	36	37	292
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	6
Adults (18-64 years)	33	35	261
From 65-84 years	3	2	25
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	39.4	38.1	
standard deviation	± 17.27	± 15.34	-
Sex: Female, Male Units: Subjects			
Female	16	20	156
Male	20	17	136
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	9	7	59
Native Hawaiian or Other Pacific Islander	0	0	2
Black or African American	5	6	51
White	22	24	174
More than one race	0	0	5
Unknown or Not Reported	0	0	1
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	4	13

Not Hispanic or Latino	35	33	277
Unknown or Not Reported	1	0	2

End points

End points reporting groups

Reporting group title	Vehicle Cream Once Daily (QD)

Reporting group description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.1% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 3.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Vehicle Cream Twice Daily (BID)

Reporting group description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream BID

Reporting group description:

Subjects or caregivers of subjects topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream BID

Reporting group description:

Subjects or caregivers of subjects topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Vehicle Cream Once Daily (QD)

Reporting group description:

Subjects or caregivers of subjects topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.1% Cream QD

Reporting group description:

Subjects or caregivers of subjects topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream QD

Reporting group description:

Subjects or caregivers of subjects topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined

on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 3.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Vehicle Cream Twice Daily (BID)

Reporting group description:

Subjects or caregivers of subjects topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream BID

Reporting group description:

Subjects or caregivers of subjects topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream BID

Reporting group description:

Subjects or caregivers of subjects topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

End point title	Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

End point description:

EASI:severity of subject's AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD scored separately for each of 4 body regions on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. FAS:all subjects who were randomly assigned to study drug and applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method based on reason for missing data.

End point type	Primary

End point timeframe:

Baseline, Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Percent change				
least squares mean (confidence interval 90%)	-44.4 (-57.3 to -31.6)	-58.3 (-71.2 to -45.5)	-64.6 (-77.1 to -52.1)	-70.1 (-82.1 to -58.0)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Percent change				
least squares mean (confidence interval 90%)	-67.9 (-80.6 to -55.3)	-47.6 (-57.5 to -37.7)	-58.6 (-67.5 to -49.7)	-75.0 (-83.8 to -66.2)

Statistical analyses

Statistical analysis title	Vehicle versus (vs) PF-06700841 0.1% Cream QD
Statistical analysis description: Analysis of covariance (ANCOVA) contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.104
Method	ANCOVA
Parameter estimate	Least square (LS) mean difference
Point estimate	-13.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-32.1
upper limit	4.3
Variability estimate	Standard error of the mean
Dispersion value	11.04

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0334
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-20.2

Confidence interval	
level	90 %
sides	2-sided
lower limit	-38.3
upper limit	-2.1
Variability estimate	Standard error of the mean
Dispersion value	11

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0086
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-25.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-43.3
upper limit	-8
Variability estimate	Standard error of the mean
Dispersion value	10.75

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0158
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-23.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.5
upper limit	-5.5
Variability estimate	Standard error of the mean
Dispersion value	10.93

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0879
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-11
Confidence interval	
level	90 %
sides	2-sided
lower limit	-24.3
upper limit	2.4
Variability estimate	Standard error of the mean
Dispersion value	8.11

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-27.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-40.7
upper limit	-14.1
Variability estimate	Standard error of the mean
Dispersion value	8.11

Secondary: Percentage of Subjects Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to (>=2) Points at Week 6: Non-responder Imputation

End point title	Percentage of Subjects Achieving Investigator's Global

	Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to (>=2) Points at Week 6: Non-responder Imputation

End point description:

IGA assesses severity of subject's AD on 5 point scale.0= clear, no inflammatory signs of AD;1= almost clear,AD not fully cleared-light pink residual lesions (except post-inflammatory hyperpigmentation),just perceptible erythema, papulation/induration lichenification,excoriation, and no oozing/crusting; 2=mild AD with light red lesions, slight but definite erythema,papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.Higher scores indicating more severity of AD.Assessment excluded soles, palms and scalp. Full analysis set (FAS) was analyzed. Non-Responder Imputation (NRI) method: subjects with missing values were considered to be non-responders.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Percentage of subjects				
number (confidence interval 90%)	10.8 (4.8 to 22.2)	29.7 (18.5 to 43.3)	33.3 (21.3 to 47.0)	40.5 (28.0 to 54.4)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Percentage of subjects				
number (confidence interval 90%)	44.4 (30.2 to 59.1)	13.9 (6.9 to 25.4)	33.3 (21.3 to 47.0)	27.0 (15.5 to 40.2)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:

Risk difference = difference in percentage of subjects.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0244
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.4
upper limit	34.7

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0113
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	22.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.8
upper limit	38.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0018
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	29.7

Confidence interval	
level	90 %
sides	2-sided
lower limit	11
upper limit	45.7

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	33.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	13.7
upper limit	49.9

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0289
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	19.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.8
upper limit	36.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1145
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	13.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.9
upper limit	29.6

Secondary: Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

End point title	Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation

End point description:

EASI:severity of subject's AD based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD scored separately for each of 4 body regions on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. FAS:all subjects who were randomly assigned to study drug and applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method based on reason for missing data.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Units on a scale				
least squares mean (confidence interval 90%)	-3.2 (-4.1 to -2.3)	-4.5 (-5.4 to -3.6)	-4.6 (-5.5 to -3.7)	-4.8 (-5.7 to -3.9)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Units on a scale				
least squares mean (confidence interval 90%)	-5.5 (-6.4 to -4.7)	-3.6 (-4.3 to -3.0)	-4.4 (-5.0 to -3.8)	-5.3 (-5.9 to -4.7)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0488
Method	ANCOVA
Parameter estimate	LS mean difference
Point estimate	-1.31
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.61
upper limit	-0.01
Variability estimate	Standard error of the mean
Dispersion value	0.79

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0413
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.37
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.66
upper limit	-0.07
Variability estimate	Standard error of the mean
Dispersion value	0.788

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.02
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.59
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.86
upper limit	-0.32
Variability estimate	Standard error of the mean
Dispersion value	0.773

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-2.33
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.58
upper limit	-1.08
Variability estimate	Standard error of the mean
Dispersion value	0.758

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: ANCOVA contained fixed factors of treatment and baseline value.	

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0727
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-0.78
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.66
upper limit	0.1
Variability estimate	Standard error of the mean
Dispersion value	0.535

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:

ANCOVA contained fixed factors of treatment and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	ANCOVA
Parameter estimate	LS Mean Difference
Point estimate	-1.64
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.52
upper limit	-0.77
Variability estimate	Standard error of the mean
Dispersion value	0.534

Secondary: Percentage of Subjects Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

End point title	Percentage of Subjects Achieving >=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

End point description:

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Subjects at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Full analysis set (FAS) included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "number of

subjects analysed (N)" signifies number of subjects evaluable for this end point. NRI method: subjects with missing values were considered to be non-responders.

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 3, 4 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	36	35	37
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	16.2 (7.3 to 29.3)	16.7 (7.5 to 30.2)	20.0 (11.0 to 33.8)	29.7 (18.5 to 43.3)
At Week 2	24.3 (14.5 to 37.0)	30.6 (18.9 to 44.0)	42.9 (30.0 to 58.1)	48.6 (34.3 to 63.0)
At Week 3	21.6 (11.2 to 34.3)	38.9 (25.4 to 53.0)	48.6 (33.8 to 63.5)	59.5 (45.6 to 72.0)
At Week 4	35.1 (22.2 to 49.3)	38.9 (25.4 to 53.0)	51.4 (36.5 to 66.2)	62.2 (48.0 to 75.2)
At Week 6	40.5 (28.0 to 54.4)	41.7 (29.0 to 56.0)	51.4 (36.5 to 66.2)	56.8 (43.2 to 70.7)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	35	35
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	44.4 (30.2 to 59.1)	13.9 (6.9 to 25.4)	28.6 (16.4 to 41.9)	25.7 (15.4 to 39.2)
At Week 2	61.1 (47.0 to 74.6)	25.0 (14.9 to 38.0)	45.7 (31.7 to 60.8)	37.1 (23.6 to 52.2)
At Week 3	58.3 (44.0 to 71.0)	33.3 (21.3 to 47.0)	51.4 (36.5 to 66.2)	57.1 (41.9 to 70.0)
At Week 4	58.3 (44.0 to 71.0)	30.6 (18.9 to 44.0)	60.0 (44.8 to 74.0)	60.0 (44.8 to 74.0)
At Week 6	61.1 (47.0 to 74.6)	30.6 (18.9 to 44.0)	60.0 (44.8 to 74.0)	60.0 (44.8 to 74.0)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:

At Week 1: Risk difference = difference in percentage of subjects.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5246
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.7
upper limit	16.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 1: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3906
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.5
upper limit	19.9

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 1: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1193
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	13.5

Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.2
upper limit	30.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 1: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0048
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	28.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	8.8
upper limit	45.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 1: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0777
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	14.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2
upper limit	31.1

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:	
At Week 1: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1245
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	11.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.3
upper limit	28

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3322
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	6.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.2
upper limit	24.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0535
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.5

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.3
upper limit	36.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0159
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	24.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.5
upper limit	41.9

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	36.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	15.4
upper limit	54

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0386
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.5
upper limit	38.8

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 2: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1485
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	12.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.4
upper limit	30.3

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.062
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	17.3

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.8
upper limit	34.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0089
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	26.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.5
upper limit	44.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	37.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	17.5
upper limit	54.7

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	36.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	15.4
upper limit	54

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0711
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2
upper limit	37.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 3: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0266
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	23.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	2.7
upper limit	42.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4173
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-15.3
upper limit	23.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1096
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.3
upper limit	35.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:	
At Week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0133
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	27
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.1
upper limit	45.7

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0304
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	23.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.6
upper limit	41.7

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0078
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	29.4

Confidence interval	
level	90 %
sides	2-sided
lower limit	7.2
upper limit	47.6

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 4: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0078
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	29.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	7.2
upper limit	47.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4966
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-18.4
upper limit	20.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2753
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.3
upper limit	30.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1036
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.2
upper limit	35.7

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0457
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20.6

Confidence interval	
level	90 %
sides	2-sided
lower limit	0.4
upper limit	39.6

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0078
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	29.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	7.2
upper limit	47.6

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 6: Risk difference = difference in percentage of subjects.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	71
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0078
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	29.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	7.2
upper limit	47.6

Secondary: Percentage of Subjects Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation

End point title	Percentage of Subjects Achieving >=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation

End point description:

The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Subjects at specified time points were asked the following question: "How would you rate your itch due to AD at the worst moment during the previous 24 hours?" The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch. Full analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "number of subjects analysed" signifies number of subjects evaluable for this end point. NRI method: subjects with missing values were considered to be non-responders.

End point type	Secondary

End point timeframe:

Baseline, Week 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	33	30	32	31
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	0.0 (0.0 to 8.2)	3.3 (0.4 to 14.0)	3.1 (0.3 to 13.1)	16.1 (8.1 to 29.7)
At Week 2	9.1 (3.4 to 20.2)	10.0 (3.7 to 22.1)	9.4 (3.5 to 20.7)	19.4 (8.8 to 32.7)
At Week 3	12.1 (5.4 to 25.1)	23.3 (12.9 to 37.6)	15.6 (7.8 to 28.7)	32.3 (18.7 to 48.2)
At Week 4	18.2 (8.2 to 31.3)	26.7 (14.0 to 41.6)	28.1 (17.0 to 43.3)	35.5 (21.3 to 51.8)
At Week 6	18.2 (8.2 to 31.3)	30.0 (18.2 to 45.5)	34.4 (20.7 to 50.0)	45.2 (29.7 to 60.1)
At Follow-up visit	9.1 (3.4 to 20.2)	30.0 (18.2 to 45.5)	21.9 (12.1 to 36.2)	19.4 (8.8 to 32.7)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	30	30	27
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	10.7 (4.0 to 23.8)	3.3 (0.4 to 14.0)	3.3 (0.4 to 14.0)	11.1 (4.2 to 24.8)
At Week 2	25.0 (13.9 to 40.0)	10.0 (3.7 to 22.1)	13.3 (5.9 to 27.9)	33.3 (20.4 to 50.0)
At Week 3	32.1 (19.7 to 47.3)	10.0 (3.7 to 22.1)	20.0 (9.1 to 33.9)	37.0 (22.1 to 54.7)
At Week 4	50.0 (33.3 to 66.7)	10.0 (3.7 to 22.1)	30.0 (18.2 to 45.5)	37.0 (22.1 to 54.7)
At Week 6	50.0 (33.3 to 66.7)	16.7 (8.3 to 30.8)	33.3 (19.3 to 49.2)	40.7 (24.8 to 58.3)

At Follow-up visit	21.4 (9.8 to 36.6)	20.0 (9.1 to 33.9)	20.0 (9.1 to 33.9)	7.4 (2.0 to 20.4)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.245
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.4
upper limit	14.9

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2575
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.3
upper limit	14

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 1	

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0087
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.7
upper limit	31

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0392
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.8
upper limit	25.4

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 1	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0

Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.2
upper limit	11.2

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: At Week 1	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1528
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	7.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.9
upper limit	22.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description: At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4989
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12.7
upper limit	15.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5419
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.6
upper limit	14.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1362
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5
upper limit	26.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0541
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	15.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.4
upper limit	33.9

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: At Week 2	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3945
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-12
upper limit	19.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: At Week 2	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0201
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	23.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.9
upper limit	41.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1372
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	11.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5.4
upper limit	28.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3924
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	3.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-11.6
upper limit	19.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0311
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	2.4
upper limit	38.3

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description: At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0392
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.8
upper limit	38.1

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: At Week 3	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1541
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10
Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.2
upper limit	26.4

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0091
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	27
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.8
upper limit	45.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2835
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	8.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.5
upper limit	27

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.27
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	9.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-8.7
upper limit	27.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0662
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	17.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.4
upper limit	36.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	31.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	9.2
upper limit	50.4

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0302
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20
Confidence interval	
level	90 %
sides	2-sided
lower limit	2.2
upper limit	38.3

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0091
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	27
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.8
upper limit	45.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1561
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	11.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.5
upper limit	30.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0753
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.7
upper limit	34.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0108
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	27
Confidence interval	
level	90 %
sides	2-sided
lower limit	5.7
upper limit	46

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	31.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	9.2
upper limit	50.4

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0775
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.9
upper limit	35.7

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0243
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	24.1

Confidence interval	
level	90 %
sides	2-sided
lower limit	3.4
upper limit	43.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description: At follow-up visit	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	63
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0234
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	20.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	3.5
upper limit	38.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: At follow-up visit	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	65
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1134
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	12.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.8
upper limit	29.3

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:	
At follow-up visit	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1362
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5
upper limit	26.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At follow-up visit	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	61
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1029
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	12.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.4
upper limit	29.8

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At follow-up visit	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0

Confidence interval	
level	90 %
sides	2-sided
lower limit	-17.9
upper limit	17.9

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: At follow-up visit	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	57
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8972
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	-12.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-28.8
upper limit	3.5

Secondary: Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit

End point title	Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit

End point description:

4 body regions: head and neck, upper limbs, trunk and lower limbs. Scalp, palms and soles were excluded. BSA calculated using handprint method. Number(No.)of handprints (size of subject's full palmer hand) fitting in affected area of body region was estimated. Maximum no. of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint = 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total no. of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD. FAS population was analysed. N=number of subjects evaluable for this endpoint and "n"=subjects evaluable for each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	36	33	35
Units: Percent change				
least squares mean (confidence interval 90%)				
At Week 1(n=34,36,33,35,34,3436)	-2.4 (-12.2 to 7.4)	-2.9 (-12.5 to 6.8)	-16.2 (-26.2 to -6.2)	-19.9 (-29.6 to -10.2)
At Week 2(n=34,33,33,33,32, 32, 33, 32)	-15.3 (-28.0 to -2.6)	-7.2 (-20.2 to 5.8)	-38.1 (-51.0 to -25.2)	-43.6 (-56.5 to -30.8)
At Week 3(n=28,29,32,34,31,23,30,33)	-17.1 (-31.0 to -3.1)	-13.1 (-27.4 to 1.1)	-50.6 (-64.4 to -36.7)	-55.9 (-69.7 to -42.0)
At Week 4(n=30,28,33,32,32,25,32,32)	-25.9 (-39.8 to -12.0)	-20.1 (-34.4 to -5.7)	-55.8 (-69.5 to -42.1)	-57.9 (-71.7 to -44.0)
At Week 6(n=29,28,31,32,31,24,32,33)	-21.6 (-38.0 to -5.3)	-39.4 (-56.1 to -22.7)	-59.4 (-75.4 to -43.5)	-63.6 (-79.5 to -47.6)
At Follow-up visit(n=29,27,32,31,26,28,30,29)	-23.6 (-39.5 to -7.6)	-24.5 (-41.0 to -8.0)	-42.7 (-58.1 to -27.2)	-37.0 (-52.6 to -21.4)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	34	36	36
Units: Percent change				
least squares mean (confidence interval 90%)				
At Week 1(n=34,36,33,35,34,3436)	-23.0 (-32.8 to -13.1)	8.5 (-8.3 to 25.3)	-16.5 (-32.9 to -0.1)	-17.0 (-33.5 to -0.5)
At Week 2(n=34,33,33,33,32, 32, 33, 32)	-39.0 (-52.1 to -26.0)	-2.5 (-14.0 to 9.1)	-34.2 (-45.4 to -22.9)	-43.1 (-54.5 to -31.6)
At Week 3(n=28,29,32,34,31,23,30,33)	-49.2 (-63.2 to -35.1)	-25.2 (-39.2 to -11.1)	-39.8 (-53.0 to -26.6)	-44.0 (-57.1 to -30.9)
At Week 4(n=30,28,33,32,32,25,32,32)	-56.7 (-70.8 to -42.7)	-34.7 (-46.1 to -23.3)	-46.4 (-56.9 to -35.9)	-57.7 (-68.2 to -47.2)
At Week 6(n=29,28,31,32,31,24,32,33)	-60.3 (-76.4 to -44.1)	-31.2 (-42.5 to -20.0)	-48.9 (-59.3 to -38.6)	-65.0 (-75.3 to -54.7)
At Follow-up visit(n=29,27,32,31,26,28,30,29)	-55.2 (-71.8 to -38.6)	-26.3 (-47.5 to -5.2)	-31.6 (-52.0 to -11.3)	-24.6 (-45.2 to -4.1)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:

At Week 1: Mixed Model Repeated Measure (MMRM) contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4781
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-0.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.2
upper limit	13.3
Variability estimate	Standard error of the mean
Dispersion value	8.33

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:

At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0522
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-13.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-27.8
upper limit	0.2
Variability estimate	Standard error of the mean
Dispersion value	8.47

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:

At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0187
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-17.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-31.4
upper limit	-3.7
Variability estimate	Standard error of the mean
Dispersion value	8.37

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:

At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.008
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-20.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.5
upper limit	-6.6
Variability estimate	Standard error of the mean
Dispersion value	8.45

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:

At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0401
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-25
Confidence interval	
level	90 %
sides	2-sided
lower limit	-48.6
upper limit	-1.5
Variability estimate	Standard error of the mean
Dispersion value	14.17

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0379
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-25.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-49.2
upper limit	-1.9
Variability estimate	Standard error of the mean
Dispersion value	14.25

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.7678
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	8.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.1
upper limit	26.3
Variability estimate	Standard error of the mean
Dispersion value	11.01

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:

At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0193
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-22.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-40.9
upper limit	-4.7
Variability estimate	Standard error of the mean
Dispersion value	10.94

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:

At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0052
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-28.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-46.5
upper limit	-10.2
Variability estimate	Standard error of the mean
Dispersion value	10.95

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:

At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0164
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-23.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-42
upper limit	-5.5
Variability estimate	Standard error of the mean
Dispersion value	11.03

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:

At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-31.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-47.8
upper limit	-15.6
Variability estimate	Standard error of the mean
Dispersion value	9.72

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-40.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-57
upper limit	-24.3
Variability estimate	Standard error of the mean
Dispersion value	9.86

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6269
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	3.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.1
upper limit	23.9
Variability estimate	Standard error of the mean
Dispersion value	12.09

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:

At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0027
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-33.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	-53.1
upper limit	-13.8
Variability estimate	Standard error of the mean
Dispersion value	11.87

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:

At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0007
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-38.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-58.5
upper limit	-19.2
Variability estimate	Standard error of the mean
Dispersion value	11.89

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:

At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0041
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-32.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-51.9
upper limit	-12.3
Variability estimate	Standard error of the mean
Dispersion value	12

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:

At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1054
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-14.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-33.9
upper limit	4.6
Variability estimate	Standard error of the mean
Dispersion value	11.61

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:

At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0542
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-18.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-38.1
upper limit	0.5
Variability estimate	Standard error of the mean
Dispersion value	11.62

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:

At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6847
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	5.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-14.2
upper limit	25.9
Variability estimate	Standard error of the mean
Dispersion value	12.12

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:

At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0062
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-29.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-49.4
upper limit	-10.3
Variability estimate	Standard error of the mean
Dispersion value	11.82

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:

At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.004
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-32
Confidence interval	
level	90 %
sides	2-sided
lower limit	-51.6
upper limit	-12.3
Variability estimate	Standard error of the mean
Dispersion value	11.89

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0054
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-30.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-50.6
upper limit	-11
Variability estimate	Standard error of the mean
Dispersion value	11.97

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1076
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-11.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-27.2
upper limit	3.9
Variability estimate	Standard error of the mean
Dispersion value	9.35

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0082
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-23
Confidence interval	
level	90 %
sides	2-sided
lower limit	-38.6
upper limit	-7.3
Variability estimate	Standard error of the mean
Dispersion value	9.42

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1051
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-17.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.2
upper limit	5.6
Variability estimate	Standard error of the mean
Dispersion value	14.14

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:

At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0034
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-37.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-60.6
upper limit	-15
Variability estimate	Standard error of the mean
Dispersion value	13.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:

At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0014
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-41.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-64.8
upper limit	-19
Variability estimate	Standard error of the mean
Dispersion value	13.83

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:

At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-38.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-61.6
upper limit	-15.6
Variability estimate	Standard error of the mean
Dispersion value	13.9

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:

At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0289
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-17.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-33
upper limit	-2.4
Variability estimate	Standard error of the mean
Dispersion value	9.22

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 6:MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-33.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	-49.2
upper limit	-18.4
Variability estimate	Standard error of the mean
Dispersion value	9.27

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4739
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-0.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-23.9
upper limit	22
Variability estimate	Standard error of the mean
Dispersion value	13.88

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	67
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0789
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-19.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-41.3
upper limit	3.2
Variability estimate	Standard error of the mean
Dispersion value	13.43

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD

Number of subjects included in analysis	69
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1611
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-13.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-35.7
upper limit	8.9
Variability estimate	Standard error of the mean
Dispersion value	13.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	68
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0124
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean Difference
Point estimate	-31.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-54.7
upper limit	-8.5
Variability estimate	Standard error of the mean
Dispersion value	13.94

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID

Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3828
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	-5.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-34.7
upper limit	24.1
Variability estimate	Standard error of the mean
Dispersion value	17.68

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:

At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.

Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	70
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5383
Method	Mixed Model Repeated Measure
Parameter estimate	LS Mean difference
Point estimate	1.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-27.9
upper limit	31.3
Variability estimate	Standard error of the mean
Dispersion value	17.8

Secondary: Percentage of Subjects Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

End point title	Percentage of Subjects Achieving >=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation

End point description:

EASI:severity of subject’s AD based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD scored separately for each of 4 body regions on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (>0 to <10%), 2 (10 to <30%), 3 (30 to <50%), 4 (50 to <70%), 5 (70 to <90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t =

trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD. FAS:all subjects who were randomly assigned to study drug and applied at least 1 dose of study drug. NRI method: subjects with missing values were considered to be non-responders.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 3, 4 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	5.4 (1.4 to 15.5)	0.0 (0.0 to 7.3)	19.4 (10.7 to 32.8)	5.4 (1.4 to 15.5)
At Week 2	8.1 (3.0 to 18.5)	10.8 (4.8 to 22.2)	27.8 (15.9 to 40.9)	24.3 (14.5 to 37.0)
At Week 3	5.4 (1.4 to 15.5)	16.2 (7.3 to 29.3)	36.1 (22.9 to 50.0)	43.2 (29.3 to 56.8)
At Week 4	24.3 (14.5 to 37.0)	21.6 (11.2 to 34.3)	38.9 (25.4 to 53.0)	43.2 (29.3 to 56.8)
At Week 6	35.1 (22.2 to 49.3)	32.4 (20.6 to 46.4)	52.8 (38.0 to 67.2)	54.1 (40.2 to 68.2)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Percentage of subjects				
number (confidence interval 90%)				
At Week 1	16.7 (7.5 to 30.2)	0.0 (0.0 to 7.5)	13.9 (6.9 to 25.4)	21.6 (11.2 to 34.3)
At Week 2	38.9 (25.4 to 53.0)	13.9 (6.9 to 25.4)	25.0 (14.9 to 38.0)	32.4 (20.6 to 46.4)
At Week 3	41.7 (29.0 to 56.0)	19.4 (10.7 to 32.8)	19.4 (10.7 to 32.8)	43.2 (29.3 to 56.8)
At Week 4	50.0 (35.3 to 64.7)	22.2 (11.6 to 35.3)	36.1 (22.9 to 50.0)	48.6 (34.3 to 63.0)
At Week 6	50.0 (35.3 to 64.7)	16.7 (7.5 to 30.2)	36.1 (22.9 to 50.0)	51.4 (37.0 to 65.7)

Statistical analyses

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD

Statistical analysis description:

At Week 1

Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream

	QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8964
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	-5.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.1
upper limit	2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0391
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	14
Confidence interval	
level	90 %
sides	2-sided
lower limit	1
upper limit	28.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0

Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.8
upper limit	10.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description: At Week 1	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0708
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	11.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.4
upper limit	25

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: At Week 1	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0122
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	13.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.7
upper limit	27

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID

Statistical analysis description:	
At Week 1	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0016
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	21.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	11
upper limit	35.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.395
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.8
upper limit	16.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0173
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	19.7

Confidence interval	
level	90 %
sides	2-sided
lower limit	4.2
upper limit	35.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0327
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	16.2
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.4
upper limit	31

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description: At Week 2	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	30.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	13.2
upper limit	46.6

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID

Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1348
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	11.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	-5
upper limit	27.2

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 2	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0328
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.5
upper limit	34.8

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0769
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	10.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	-1.8
upper limit	24.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description: At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0005
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	30.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	13.2
upper limit	46

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description: At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	37.8
Confidence interval	
level	90 %
sides	2-sided
lower limit	22.1
upper limit	53.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD

Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	36.3
Confidence interval	
level	90 %
sides	2-sided
lower limit	19.7
upper limit	51.8

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	-16.5
upper limit	16.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description:	
At Week 3	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0173
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	23.8

Confidence interval	
level	90 %
sides	2-sided
lower limit	4.5
upper limit	41.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5663
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	-2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-19.9
upper limit	14.2

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1243
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	14.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.8
upper limit	32.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD

Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.046
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.5
upper limit	36.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.013
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	25.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	4.8
upper limit	43.3

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description:	
At Week 4	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1194
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	13.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-4.2
upper limit	31.4

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: At Week 4	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0097
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	26.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	6.5
upper limit	44.4

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.1% Cream QD
Statistical analysis description: At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.1% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.5556
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	-2.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	-21
upper limit	16.1

Statistical analysis title	Vehicle Cream QD vs PF-06700841 0.3% Cream QD

Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 0.3% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0761
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	17.6
Confidence interval	
level	90 %
sides	2-sided
lower limit	-2.5
upper limit	36.5

Statistical analysis title	Vehicle Cream QD vs PF-06700841 1.0% Cream QD
Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 1.0% Cream QD
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0583
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	18.9
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.8
upper limit	37.6

Statistical analysis title	Vehicle Cream QD vs PF-06700841 3.0% Cream QD
Statistical analysis description:	
At Week 6	
Comparison groups	Vehicle Cream Once Daily (QD) v PF-06700841 3.0% Cream QD
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1245
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	14.9

Confidence interval	
level	90 %
sides	2-sided
lower limit	-5
upper limit	33.7

Statistical analysis title	Vehicle Cream BID vs PF-06700841 0.3% Cream BID
Statistical analysis description: At Week 6	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 0.3% Cream BID
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0382
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	19.4
Confidence interval	
level	90 %
sides	2-sided
lower limit	1.5
upper limit	36.5

Statistical analysis title	Vehicle Cream BID vs PF-06700841 1.0% Cream BID
Statistical analysis description: At Week 6	
Comparison groups	Vehicle Cream Twice Daily (BID) v PF-06700841 1.0% Cream BID
Number of subjects included in analysis	73
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0011
Method	Chan and Zhang Exact Method
Parameter estimate	Risk difference (RD)
Point estimate	34.7
Confidence interval	
level	90 %
sides	2-sided
lower limit	13.2
upper limit	51.4

Secondary: Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment-Emergent Adverse Events

	(AEs) and Serious Adverse Events (SAEs)

End point description:

An AE was any untoward medical occurrence in a subject who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent AEs were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug.

End point type	Secondary

End point timeframe:

Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Subjects				
TEAEs	18	17	11	12
SAEs	0	0	0	0

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Subjects				
TEAEs	10	17	9	14
SAEs	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Pre-defined Criteria For Vital Sign

End point title	Number of Subjects With Pre-defined Criteria For Vital Sign

End point description:

Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting (S)DBP: change(C) of >= 20 millimeter of mercury (mmHg) increase (inc.), b) sitting DBP: change of >=20mmHg decrease(dec.), c) supine(Sup.) DBP: less than (<) 50 mmHg, d) supine DBP: change of >= 20mmHg increase, e) supine DBP: change of >= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: <90 mmHg, b) sitting SBP: change of >=30mmHg increase, c) sitting SBP: change of >=30mmHg decrease, d) supine SBP: change of >=30mmHg increase, e) supine SBP: change of >=30mmHg decrease and f) Supine SBP: value(Val.) <90mmHg. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "number of subjects analysed:" signifies number of subjects evaluable for this end point and "n" signifies subjects evaluable for the each

specified time point.

End point type	Secondary

End point timeframe:

Baseline up to Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	20	25	18
Units: Subjects				
SDBP:Change>=20mmHg inc.(n=12,13,9,15,12,7,12,11)	0	0	1	2
SDBP:Change>= 20mmHg dec.(n=12,13,9,15,12,7,12,11)	1	0	0	1
Supi.DBP:Val.<50 mmHg(n=21,20,25,18,21,19,22,22)	0	0	0	0
Sup.DBP:C>=20mmHg inc.(n=21,20,25,18,21,19,22,22)	0	1	1	2
Sup.DBP:C>=20mmHg dec.(n=21,20,25,18,21,19,22,22)	0	0	0	0
Sitting SBP: <90mmHg(n=12,13,9,15,12,7,12,11)	0	0	0	1
SittingSBP:C>=30mmHg inc.(n=12,13,9,15,12,7,12,11)	0	0	0	1
SittingSBP:C>=30mmHgdec.(n=12,13,9,15,12,7,12,11)	0	0	0	0
SupineSBP:C>=30mmHginc.(n=21,20,25,18,21,19,22,22)	1	0	1	0
SupineSBP:C>=30mmHgdec.(n=21,20,25,18,21,19,22,22)	0	0	1	0
Supine SBP:Val.<90mmHg(n=21,20,25,18,21,1	0	1	1	0

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	19	22	22
Units: Subjects				
SDBP:Change>=20mmHg inc.(n=12,13,9,15,12,7,12,11)	0	0	0	0
SDBP:Change>= 20mmHg dec.(n=12,13,9,15,12,7,12,11)	0	1	0	0
Supi.DBP:Val.<50 mmHg(n=21,20,25,18,21,19,22,22)	0	1	0	0
Sup.DBP:C>=20mmHg inc.(n=21,20,25,18,21,19,22,22)	1	0	1	0
Sup.DBP:C>=20mmHg dec.(n=21,20,25,18,21,19,22,22)	0	0	1	0
Sitting SBP: <90mmHg(n=12,13,9,15,12,7,12,11)	0	0	0	0

SittingSBP:C>=30mmHg inc.(n=12,13,9,15,12,7,12,11)	0	0	0	1
SittingSBP:C>=30mmHgdec.(n=12,13,9,15,12,7,12,11)	1	0	0	0
SupineSBP:C>=30mmHginc.(n=21,20,25,18,21,19,22,22)	0	1	1	0
SupineSBP:C>=30mmHgdec.(n=21,20,25,18,21,19,22,22)	0	0	2	0
Supine SBP:Val.<90mmHg(n=21,20,25,18,21,1	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Laboratory Abnormalities

End point title	Number of Subjects With Laboratory Abnormalities

End point description:

Hemoglobin(HGB),hematocrit,erythrocytes(ery.),HDL cholesterol(chl.)<0.8*lower limit of normal(LLN);reticulocytes (ret.), ret./ery.(%)<0.5*LLN,>1.5*upper limit of normal(ULN);ery.mean corpuscular(EMC) volume,EMC HGB,EMC HGBconcentration,potassium,chloride,calcium,bicarbonate<0.9*LLN,>1.1*ULN;platelets<0.5*LLN,>1.75*ULN;leukocytes (leu.),glucose<0.6*LLN,>1.5*ULN;lymphocytes (lym.),lym./leu.(%),neutrophils(neu.),neu./leu.(%),protein,albumin <0.8*LLN,>1.2*ULN;basophils(bas.),bas./leu.(%),eosinophils(eos.),eos./leu.,monocytes(mon.),mon./leu.(%),urate >1.2*ULN;bilirubin (total,direct,indirect)>1.5*ULN;aspartate/alanine aminotransferase,gamma glutamyl transferase, lactate dehydrogenase,alkaline phosphatase>3.0*ULN;urea nitrogen, creatinine,triglycerides,chl.>1.3*ULN; sodium <0.95*LLN,>1.05*ULN; creatine kinase >2.0*ULN;Urine: pH<4.5,>8;glucose,ketones,

End point type	Secondary

End point timeframe:

Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	35	35	37
Units: Subjects	26	22	23	22

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	36	36	36
Units: Subjects	16	21	24	24

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Change in Electrocardiogram (ECG) Findings

End point title	Number of Subjects With Clinically Significant Change in Electrocardiogram (ECG) Findings

End point description:

Clinically significant ECG criteria included PR interval: value greater than (>) 280 millisecond (msec), percentage change greater than equal to (>=) 25/50 percentage, QRS interval: value >120 msec, percentage change >= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30<=change<60. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "number of subjects analysed" signifies number of subjects evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline up to Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	6	7	9
Units: Subjects				
PR interval : value >280	0	0	0	0
PR interval : %change>=25/50%	0	1	1	0
QRS interval: value >120	0	0	0	0
QRS interval: %Change>=50%	0	0	0	0
QTCF: 450	0	0	1	1
QTCF: 30<=Change<60	0	1	1	1

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	7
Units: Subjects				
PR interval : value >280	1	0	0	0
PR interval : %change>=25/50%	1	0	2	0
QRS interval: value >120	0	0	1	1
QRS interval: %Change>=50%	0	1	0	0
QTCF: 450	0	1	0	0
QTCF: 30<=Change<60	1	2	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point. Change at follow-up= CAF.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	32	32	33
Units: Units per litre				
arithmetic mean (standard deviation)				
Change at week 1(n=32,32,32,30,32,32,34,33)	0.4 (± 25.99)	-7.4 (± 30.20)	-5.3 (± 16.99)	-9.3 (± 22.65)
Change at week 2(n=32,27,30,33,27,28,31,30)	-8.8 (± 21.56)	-7.8 (± 27.99)	-1.9 (± 18.18)	-8.8 (± 23.70)
Change at week 4(n=26,27,30,31,30,24,27,29)	-8.6 (± 23.93)	-5.4 (± 22.87)	-9.3 (± 19.61)	-12.1 (± 28.54)
Change at week 6(n=30,26,31,31,28,23,31,32)	-8.8 (± 18.25)	-8.1 (± 32.02)	-1.5 (± 32.42)	-6.4 (± 28.53)
CAF visit(n=26,28,31,30,27,30,30,26)	-12.3 (± 24.82)	-12.0 (± 28.83)	4.0 (± 43.45)	-2.7 (± 26.27)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	32	32	34	33
Units: Units per litre				
arithmetic mean (standard deviation)				
Change at week 1(n=32,32,32,30,32,32,34,33)	-18.4 (± 33.42)	-8.0 (± 34.51)	-8.0 (± 19.37)	-4.3 (± 29.08)
Change at week 2(n=32,27,30,33,27,28,31,30)	-15.8 (± 42.19)	-0.3 (± 22.81)	-8.0 (± 22.31)	-4.9 (± 24.49)
Change at week 4(n=26,27,30,31,30,24,27,29)	-16.3 (± 33.97)	-1.0 (± 29.29)	-19.5 (± 19.94)	-3.7 (± 24.96)
Change at week 6(n=30,26,31,31,28,23,31,32)	-18.2 (± 33.86)	-9.7 (± 20.68)	-11.2 (± 22.34)	-7.0 (± 24.65)
CAF visit(n=26,28,31,30,27,30,30,26)	-15.1 (± 38.23)	-11.3 (± 29.39)	-13.3 (± 25.37)	0.2 (± 16.48)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analyzed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point. CAW: change at week. CAF: change at follow-up.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	35
Units: Gram per decilitre				
arithmetic mean (standard deviation)				
Protein: CAW 1(n=34,35,33,35,34,34,36,35)	-0.01 (± 0.439)	-0.04 (± 0.294)	-0.14 (± 0.433)	-0.04 (± 0.264)
Protein:CAW2(n=34,33,32,34,32,30,33,32)	-0.09 (± 0.383)	0.03 (± 0.303)	-0.18 (± 0.402)	-0.01 (± 0.275)
Protein: CAW4(n-29,28,33,31,32,24,31,30)	-0.10 (± 0.380)	0.07 (± 0.315)	-0.08 (± 0.429)	-0.03 (± 0.341)
Protein: CAW6(n=30,27,31,32,31,24,32,33)	-0.13 (± 0.403)	0.13 (± 0.379)	-0.19 (± 0.452)	0.01 (± 0.368)
Protein: CAFvisit(n=30,29,32,32,29,31,32,30)	-0.07 (± 0.341)	0.05 (± 0.457)	-0.15 (± 0.481)	-0.04 (± 0.404)
Albumin:CAW 1(n=34,35,33,35,34,34,36,35)	-0.04 (± 0.269)	-0.05 (± 0.205)	-0.10 (± 0.283)	-0.02 (± 0.177)
Albumin:CAW 2(n=34,33,32,34,32,30,33,32)	-0.06 (± 0.235)	0.02 (± 0.201)	-0.10 (± 0.256)	-0.02 (± 0.204)
Albumin: CAW4(n-29,28,33,31,32,24,31,30)	-0.08 (± 0.245)	0.07 (± 0.172)	-0.08 (± 0.285)	0.01 (± 0.239)
Albumin:CAW 6(n=30,27,31,32,31,24,32,33)	-0.08 (± 0.259)	0.08 (± 0.245)	-0.14 (± 0.333)	-0.02 (± 0.269)
Albumin:CAF visit(n=30,29,32,32,29,31,32,30)	-0.06 (± 0.247)	0.10 (± 0.260)	-0.09 (± 0.277)	-0.04 (± 0.295)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	36	36	35
Units: Gram per decilitre				
arithmetic mean (standard deviation)				
Protein: CAW 1(n=34,35,33,35,34,34,36,35)	-0.03 (± 0.421)	-0.10 (± 0.360)	-0.01 (± 0.344)	-0.02 (± 0.301)
Protein:CAW2(n=34,33,32,34,32,30,33,32)	0.01 (± 0.561)	0.02 (± 0.503)	-0.04 (± 0.286)	-0.10 (± 0.299)
Protein: CAW4(n-29,28,33,31,32,24,31,30)	-0.04 (± 0.465)	-0.18 (± 0.292)	-0.15 (± 0.242)	0.03 (± 0.280)
Protein: CAW6(n=30,27,31,32,31,24,32,33)	-0.03 (± 0.405)	-0.10 (± 0.424)	-0.09 (± 0.368)	-0.09 (± 0.310)
Protein: CAFvisit(n=30,29,32,32,29,31,32,30)	0.03 (± 0.481)	-0.18 (± 0.471)	-0.09 (± 0.398)	0.02 (± 0.299)
Albumin:CAW 1(n=34,35,33,35,34,34,36,35)	0.00 (± 0.256)	-0.05 (± 0.218)	-0.03 (± 0.246)	0.00 (± 0.169)
Albumin:CAW 2(n=34,33,32,34,32,30,33,32)	-0.01 (± 0.283)	0.02 (± 0.266)	-0.03 (± 0.174)	-0.06 (± 0.202)
Albumin: CAW4(n-29,28,33,31,32,24,31,30)	0.04 (± 0.292)	-0.10 (± 0.232)	-0.08 (± 0.180)	0.03 (± 0.224)
Albumin:CAW 6(n=30,27,31,32,31,24,32,33)	-0.00 (± 0.218)	-0.03 (± 0.252)	-0.07 (± 0.244)	-0.05 (± 0.227)
Albumin:CAF visit(n=30,29,32,32,29,31,32,30)	-0.01 (± 0.346)	-0.09 (± 0.262)	-0.02 (± 0.211)	0.06 (± 0.181)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	35
Units: Microgram per decilitre				
arithmetic mean (standard deviation)				
Urea nitrogen:CAW 1(n=34,35,33,35,34,34,36,35)	0.9 (± 4.57)	0.6 (± 3.04)	0.1 (± 3.12)	1.0 (± 3.19)
Urea nitrogen:CAW2(n=34,33,32,34,32,30,3	0.8 (± 3.89)	0.0 (± 2.71)	0.6 (± 3.54)	0.9 (± 3.18)
Urea nitrogen:CAW4(n-29,28,33,31,32,24,31,30)	0.6 (± 3.39)	0.0 (± 3.04)	-0.0 (± 2.67)	1.4 (± 3.06)
Urea nitrogen:CAW 6(n=30,27,31,32,31,24,32,33)	0.7 (± 2.84)	-0.2 (± 3.11)	-0.6 (± 3.61)	0.9 (± 3.27)
Urea nitrogen:CAFvisit(n=30,29,32,32,29,31,	0.0 (± 3.17)	-0.3 (± 3.13)	0.4 (± 2.60)	1.2 (± 4.22)
Urate:CAW1(n=34,35,33,35,34,34,36,35)	0.16 (± 0.807)	0.01 (± 0.606)	0.16 (± 0.678)	-0.01 (± 0.561)
Urate: CAW2(n=34,33,32,34,32,30,33,32)	0.30 (± 0.990)	-0.11 (± 0.655)	0.12 (± 0.617)	-0.03 (± 0.649)
Urate: CAW 4(n-29,28,33,31,32,24,31,30)	0.21 (± 0.497)	0.14 (± 0.731)	0.06 (± 0.756)	-0.06 (± 0.621)
Urate: CAW 6(n=30,27,31,32,31,24,32,33)	0.13 (± 0.728)	0.07 (± 0.984)	-0.02 (± 0.831)	0.06 (± 0.630)
Urate: CAW visit(n=30,29,32,32,29,31,32,30)	-0.11 (± 0.721)	-0.33 (± 0.753)	0.05 (± 0.763)	-0.21 (± 0.554)
Calcium:CAW 1(n=34,35,33,35,34,34,36,35)	0.01 (± 0.419)	0.01 (± 0.259)	-0.06 (± 0.377)	-0.02 (± 0.248)
Calcium:CAW2(n=34,33,32,34,32,30,33,32)	-0.08 (± 0.417)	0.00 (± 0.268)	-0.10 (± 0.362)	0.05 (± 0.296)
Calcium:CAW4(n-29,28,33,31,32,24,31,30)	-0.04 (± 0.354)	0.11 (± 0.329)	-0.07 (± 0.345)	0.05 (± 0.272)
Calcium:CAW6(n=30,27,31,32,31,24,32,33)	-0.04 (± 0.355)	0.10 (± 0.303)	-0.21 (± 0.393)	0.03 (± 0.315)
Calcium:CAFvisit(n=30,29,32,32,29,31,32,30)	0.00 (± 0.317)	-0.01 (± 0.345)	-0.08 (± 0.409)	0.00 (± 0.323)
Glucose:CAW 1(n=34,35,33,34,34,33,36,35)	4.9 (± 8.73)	5.7 (± 13.97)	3.4 (± 14.62)	4.5 (± 8.60)
Glucose:CAW2(n=33,33,32,34,32,30,33,32)	9.7 (± 23.71)	1.2 (± 17.34)	0.6 (± 10.97)	3.2 (± 12.63)
Glucose:CAW 4(n-29,28,33,31,32,24,31,30)	7.3 (± 15.60)	0.5 (± 12.50)	-1.2 (± 15.86)	4.5 (± 13.99)
Glucose:CAW6(n=30,27,31,32,31,24,32,33)	3.5 (± 9.19)	2.4 (± 17.55)	-1.7 (± 10.62)	2.1 (± 13.80)
Glucose:CAFvisit(n=30,29,32,32,29,31,32,30)	4.5 (± 11.58)	2.2 (± 11.45)	4.8 (± 13.28)	4.6 (± 14.77)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	34	36	35
Units: Microgram per decilitre				
arithmetic mean (standard deviation)				
Urea nitrogen:CAW 1(n=34,35,33,35,34,34,36,35)	1.0 (± 3.05)	0.2 (± 2.19)	0.4 (± 3.38)	-0.1 (± 2.65)

Urea nitrogen:CAW2(n=34,33,32,34,32,30,3	0.5 (± 3.63)	0.6 (± 4.19)	0.8 (± 2.99)	0.4 (± 3.28)
Urea nitrogen:CAW4(n-29,28,33,31,32,24,31,30)	0.5 (± 3.84)	-0.7 (± 2.96)	1.3 (± 2.81)	-0.2 (± 3.61)
Urea nitrogen:CAW 6(n=30,27,31,32,31,24,32,33)	0.3 (± 3.82)	-0.8 (± 3.24)	0.2 (± 3.52)	-0.4 (± 3.69)
Urea nitrogen:CAFvisit(n=30,29,32,32,29,31,	0.2 (± 2.87)	0.8 (± 3.78)	0.5 (± 3.42)	0.1 (± 3.78)
Urate:CAW1(n=34,35,33,35,34,34,36,35)	0.00 (± 0.739)	0.05 (± 0.661)	-0.02 (± 0.704)	-0.14 (± 0.890)
Urate: CAW2(n=34,33,32,34,32,30,33,32)	-0.15 (± 0.842)	0.27 (± 1.025)	-0.03 (± 0.718)	-0.37 (± 1.059)
Urate: CAW 4(n-29,28,33,31,32,24,31,30)	-0.14 (± 0.856)	0.22 (± 0.806)	-0.21 (± 0.663)	-0.16 (± 0.713)
Urate: CAW 6(n=30,27,31,32,31,24,32,33)	-0.02 (± 0.649)	0.06 (± 0.534)	-0.11 (± 0.827)	-0.21 (± 1.084)
Urate: CAW visit(n=30,29,32,32,29,31,32,30)	-0.02 (± 0.810)	0.02 (± 0.590)	-0.08 (± 0.677)	-0.20 (± 0.989)
Calcium:CAW 1(n=34,35,33,35,34,34,36,35)	0.07 (± 0.386)	-0.02 (± 0.303)	-0.01 (± 0.295)	0.09 (± 0.318)
Calcium:CAW2(n=34,33,32,34,32,30,33,32)	0.07 (± 0.423)	0.03 (± 0.389)	-0.10 (± 0.293)	-0.01 (± 0.244)
Calcium:CAW4(n-29,28,33,31,32,24,31,30)	0.00 (± 0.376)	-0.08 (± 0.309)	-0.03 (± 0.257)	0.10 (± 0.341)
Calcium:CAW6(n=30,27,31,32,31,24,32,33)	0.00 (± 0.397)	-0.05 (± 0.335)	-0.05 (± 0.464)	-0.04 (± 0.337)
Calcium:CAFvisit(n=30,29,32,32,29,31,32,30)	0.10 (± 0.441)	-0.05 (± 0.419)	0.01 (± 0.378)	0.05 (± 0.356)
Glucose:CAW 1(n=34,35,33,34,34,33,36,35)	4.4 (± 16.14)	4.5 (± 29.90)	5.6 (± 13.14)	3.3 (± 13.58)
Glucose:CAW2(n=33,33,32,34,32,30,33,32)	3.1 (± 10.00)	-1.9 (± 13.51)	7.9 (± 16.67)	2.7 (± 18.07)
Glucose:CAW 4(n-29,28,33,31,32,24,31,30)	2.8 (± 20.20)	1.3 (± 24.01)	10.7 (± 26.13)	3.4 (± 18.33)
Glucose:CAW6(n=30,27,31,32,31,24,32,33)	-0.5 (± 9.77)	-3.4 (± 16.37)	4.3 (± 12.23)	1.5 (± 12.62)
Glucose:CAFvisit(n=30,29,32,32,29,31,32,30)	6.0 (± 13.79)	6.2 (± 16.75)	9.1 (± 17.21)	2.0 (± 22.43)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	35
Units: Milliequivalents per litre				
arithmetic mean (standard deviation)				
Sodium:CAW 1(n=34,35,33,35,34,34,36,35)	0.1 (± 2.34)	-0.0 (± 1.77)	-0.7 (± 2.04)	-0.6 (± 2.17)
Sodium:CAW2(n=34,33,32,34,32,30,33,32)	-0.5 (± 2.23)	-0.3 (± 1.89)	-0.1 (± 2.39)	-0.2 (± 2.18)
Sodium:CAW4(n-29,28,33,31,32,24,31,30)	-0.3 (± 2.70)	0.6 (± 1.83)	-0.2 (± 2.44)	-0.7 (± 2.71)
Sodium:CAW6(n=30,27,31,32,31,24,32,33)	-0.8 (± 2.31)	0.0 (± 2.39)	-0.2 (± 2.23)	-0.9 (± 2.40)
Sodium:CAF visit(n=30,29,32,32,29,31,32,30)	-0.4 (± 3.26)	0.5 (± 2.50)	-0.1 (± 2.45)	-0.3 (± 2.41)
Potassium:CAW1(n=34,35,33,35,34,34,36,34)	-0.00 (± 0.363)	0.08 (± 0.282)	0.03 (± 0.372)	0.02 (± 0.347)
Potassium:CAW2(n=33,33,32,34,32,30,33,32)	-0.14 (± 0.367)	0.04 (± 0.298)	-0.07 (± 0.338)	0.04 (± 0.359)
Potassium:CAW4(n-29,28,33,31,32,24,31,30)	0.01 (± 0.389)	-0.06 (± 0.285)	-0.02 (± 0.350)	-0.01 (± 0.327)
Potassium:CAW6(n=30,27,31,32,31,24,32,33)	-0.09 (± 0.373)	0.03 (± 0.295)	-0.06 (± 0.332)	0.03 (± 0.407)
Potassium:CAF visit(n=30,29,32,32,29,31,32,30)	-0.11 (± 0.379)	0.10 (± 0.375)	0.03 (± 0.394)	0.04 (± 0.351)
Chloride:CAW1(n=34,35,33,35,34,34,36,35)	0.1 (± 2.11)	0.3 (± 1.86)	0.3 (± 1.57)	0.0 (± 2.54)
Chloride:CAW2(n=34,33,32,34,32,30,33,32)	-0.2 (± 2.52)	-0.2 (± 2.08)	0.7 (± 2.03)	0.2 (± 2.50)
Chloride:CAW4(n-29,28,33,31,32,24,31,30)	0.3 (± 2.05)	0.6 (± 1.89)	0.2 (± 2.68)	-0.4 (± 2.23)
Chloride:CAW6(n=30,27,31,32,31,24,32,33)	-0.6 (± 1.98)	0.1 (± 2.27)	0.0 (± 2.34)	-0.5 (± 2.44)
Chloride:CAFvisit(n=30,29,32,32,29,31,32,30)	0.6 (± 2.97)	-0.3 (± 2.16)	0.8 (± 2.64)	0.1 (± 2.41)
Bicarbonate:CAW1(n=34,35,33,33,34,33,36,35)	0.13 (± 2.548)	-0.38 (± 1.759)	-0.20 (± 1.965)	-0.18 (± 1.768)
Bicarbonate: CAW2(n=34,33,32,34,31,30,33,32)	0.08 (± 2.229)	-0.40 (± 2.151)	-0.51 (± 1.956)	0.10 (± 2.129)
Bicarbonate:CAW4(n-29,28,33,31,32,24,30,30)	0.21 (± 2.739)	0.05 (± 2.128)	-0.24 (± 2.484)	0.34 (± 1.868)
Bicarbonate:CAW6(n=30,27,31,32,31,24,32,33)	0.52 (± 2.560)	-0.44 (± 2.598)	0.66 (± 2.132)	0.27 (± 2.204)
Bicarbonate:CAFvisit(n=30,29,32,32,29,31,32,30)	-0.02 (± 2.916)	0.66 (± 2.209)	0.41 (± 2.056)	0.75 (± 2.386)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	34	36	35

Units: Milliequivalents per litre				
arithmetic mean (standard deviation)				
Sodium:CAW 1(n=34,35,33,35,34,34,36,35)	-0.4 (± 3.50)	0.4 (± 1.97)	0.0 (± 2.08)	-0.1 (± 3.39)
Sodium:CAW2(n=34,33,32,34,32,30,33,32)	-0.4 (± 3.61)	-0.2 (± 2.61)	-0.5 (± 2.20)	-0.3 (± 3.45)
Sodium:CAW4(n-29,28,33,31,32,24,31,30)	-0.4 (± 3.08)	-0.4 (± 2.72)	-0.1 (± 1.77)	-0.3 (± 3.28)
Sodium:CAW6(n=30,27,31,32,31,24,32,33)	-0.9 (± 3.55)	0.9 (± 2.50)	-0.1 (± 2.23)	-0.5 (± 2.49)
Sodium:CAF visit(n=30,29,32,32,29,31,32,30)	-0.8 (± 3.59)	0.7 (± 1.94)	-0.1 (± 2.46)	0.1 (± 3.32)
Potassium:CAW1(n=34,35,33,35,34,34,36,34)	0.07 (± 0.343)	0.01 (± 0.337)	0.00 (± 0.429)	0.20 (± 0.464)
Potassium:CAW2(n=33,33,32,34,32,30,33,32)	0.07 (± 0.346)	0.00 (± 0.245)	-0.16 (± 0.438)	-0.02 (± 0.322)
Potassium:CAW4(n-29,28,33,31,32,24,31,30)	0.05 (± 0.375)	-0.09 (± 0.300)	-0.03 (± 0.415)	0.26 (± 0.350)
Potassium:CAW6(n=30,27,31,32,31,24,32,33)	-0.06 (± 0.262)	-0.06 (± 0.309)	-0.10 (± 0.355)	0.09 (± 0.388)
Potassium:CAF visit(n=30,29,32,32,29,31,32,30)	0.12 (± 0.358)	0.05 (± 0.293)	-0.09 (± 0.475)	0.26 (± 0.460)
Chloride:CAW1(n=34,35,33,35,34,34,36,35)	0.0 (± 2.66)	0.6 (± 2.11)	0.5 (± 2.02)	0.5 (± 2.83)
Chloride:CAW2(n=34,33,32,34,32,30,33,32)	-0.2 (± 2.87)	0.4 (± 2.70)	0.4 (± 2.15)	0.2 (± 2.99)
Chloride:CAW4(n-29,28,33,31,32,24,31,30)	-0.3 (± 2.16)	0.3 (± 3.28)	1.0 (± 2.21)	-0.2 (± 2.57)
Chloride:CAW6(n=30,27,31,32,31,24,32,33)	-0.4 (± 3.05)	0.5 (± 2.93)	0.9 (± 2.73)	0.0 (± 2.32)
Chloride:CAFvisit(n=30,29,32,32,29,31,32,30)	-0.4 (± 2.90)	1.3 (± 2.11)	0.3 (± 2.35)	0.4 (± 3.16)
Bicarbonate:CAW1(n=34,35,33,33,34,33,36,35)	0.28 (± 1.638)	0.09 (± 2.209)	-0.21 (± 2.388)	-0.02 (± 1.651)
Bicarbonate: CAW2(n=34,33,32,34,31,30,33,32)	-0.13 (± 1.931)	-0.15 (± 2.341)	-0.60 (± 2.354)	-0.07 (± 1.828)
Bicarbonate:CAW4(n-29,28,33,31,32,24,30,30)	0.02 (± 2.011)	0.14 (± 1.286)	-0.00 (± 2.695)	0.02 (± 1.704)
Bicarbonate:CAW6(n=30,27,31,32,31,24,32,33)	0.12 (± 2.407)	0.63 (± 2.096)	-0.19 (± 2.038)	-0.20 (± 2.217)
Bicarbonate:CAFvisit(n=30,29,32,32,29,31,32,30)	0.43 (± 2.162)	0.08 (± 1.643)	0.18 (± 2.300)	1.09 (± 2.049)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	37	33	34
Units: Gram per decilitre				
arithmetic mean (standard deviation)				
CAW 1(n=34,35,32,34,34,33,35,34)	-0.01 (± 0.790)	-0.22 (± 0.620)	-0.36 (± 0.775)	-0.12 (± 0.678)
CAW 2(n=34,33,32,34,32,30,33,31)	-0.16 (± 0.636)	-0.09 (± 0.566)	-0.64 (± 0.715)	-0.24 (± 0.657)
CAW 4(n-28,27,33,31,32,25,30,30)	0.03 (± 0.725)	-0.17 (± 0.630)	-0.48 (± 0.659)	-0.25 (± 0.628)
CAW 6(n=29,27,31,32,31,24,32,33)	-0.13 (± 0.832)	-0.06 (± 0.614)	-0.48 (± 0.767)	-0.03 (± 0.617)
CAF visit(n=30,29,30,32,30,31,32,30)	0.05 (± 0.613)	-0.04 (± 0.717)	-0.49 (± 0.777)	-0.09 (± 0.784)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	35	34
Units: Gram per decilitre				
arithmetic mean (standard deviation)				
CAW 1(n=34,35,32,34,34,33,35,34)	-0.26 (± 0.726)	-0.19 (± 0.698)	-0.21 (± 0.584)	-0.27 (± 0.679)
CAW 2(n=34,33,32,34,32,30,33,31)	-0.22 (± 0.798)	-0.16 (± 0.830)	-0.25 (± 0.625)	-0.32 (± 0.793)
CAW 4(n-28,27,33,31,32,25,30,30)	-0.06 (± 0.821)	-0.27 (± 0.789)	-0.32 (± 0.701)	-0.20 (± 0.658)
CAW 6(n=29,27,31,32,31,24,32,33)	-0.11 (± 0.775)	-0.22 (± 0.724)	-0.21 (± 0.833)	-0.28 (± 0.683)
CAF visit(n=30,29,30,32,30,31,32,30)	0.00 (± 0.773)	-0.27 (± 0.756)	-0.12 (± 0.826)	-0.18 (± 0.740)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Hematology - Hematocrit,

	Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	34
Units: Percentage of cells				
arithmetic mean (standard deviation)				
Hematocrit: CAW1(n=34,35,32,34,34,33,35,33)	0.2 (± 2.51)	-0.8 (± 2.11)	-1.3 (± 2.61)	-0.4 (± 2.27)
Hematocrit: CAW2(n=34,33,32,34,32,30,33,30)	-0.5 (± 2.19)	-0.8 (± 2.12)	-1.8 (± 2.42)	-0.9 (± 2.32)
Hematocrit: CAW4(n=28,27,33,31,30,31,25,30)	0.0 (± 2.45)	-0.8 (± 1.96)	-1.8 (± 2.06)	-0.8 (± 2.34)
Hematocrit:CAW6(n=29,27,31,32,31,24,32,33)	-0.6 (± 2.47)	-0.9 (± 1.93)	-1.6 (± 2.64)	-0.7 (± 2.23)
Hematocrit: CAFvisit(n=30,29,30,32,30,31,32,30)	0.3 (± 2.49)	-0.7 (± 2.24)	-1.4 (± 3.05)	-0.7 (± 2.39)
Reticulocytes/Ery.CAW1(n=31,31, 29,29,27,28,31,27)	0.03 (± 0.317)	0.14 (± 0.378)	0.02 (± 0.483)	0.06 (± 0.364)
Reticulocytes/Ery.CAW2(n=31,30,29,29, 25,26,29,24)	-0.03 (± 0.382)	0.17 (± 0.325)	0.09 (± 0.413)	-0.02 (± 0.473)
Reticulocytes/Ery.CAW4(n=25,24,30,27, 25,23,26,23)	0.16 (± 0.596)	-0.08 (± 0.359)	0.01 (± 0.460)	0.19 (± 0.429)
Reticulocytes/Ery.CAW6(n=26,25,28,28, 24,22,28,26)	-0.06 (± 0.382)	0.02 (± 0.361)	0.02 (± 0.473)	0.01 (± 0.486)
Ret./Ery.CAFvisit(n=27,25,27, 27, 23, 27, 27, 23)	-0.11 (± 0.396)	-0.02 (± 0.384)	0.10 (± 0.435)	-0.10 (± 0.398)
Lym./Leuk.CAW1(n=34,35,32,34,3433, 35, 34)	-0.43 (± 6.772)	0.68 (± 5.814)	2.33 (± 5.616)	0.06 (± 4.765)
Lym./Leukocytes:CAW2(n=34,33,32,34, 32,30,33,31)	0.20 (± 6.175)	0.84 (± 7.544)	1.68 (± 5.208)	1.50 (± 5.639)
Lym./Leukocytes:CAW4(n=28,27,33,31, 32,25,20,30)	1.58 (± 7.591)	0.51 (± 7.297)	1.43 (± 5.298)	0.43 (± 7.586)
Lym./Leukocytes:CAW6(n=29,27,31,32, 31,24,32,33)	-0.92 (± 6.701)	-0.06 (± 5.461)	0.82 (± 6.685)	1.28 (± 5.881)
Lym./Leuk.:CAFvisit(n=30,29,30,32,30, 31,32,30)	1.53 (± 6.219)	1.25 (± 4.974)	1.61 (± 6.597)	-0.85 (± 6.367)
Neu./Leukocytes:CAW1(n=34,35,32,34, 34,33,35,34)	0.57 (± 7.515)	-0.95 (± 6.957)	-2.93 (± 6.191)	0.30 (± 5.755)
Neu./Leukocytes:CAW2(n=34,33,32,34, 32,30,33,31)	-0.12 (± 7.827)	-0.34 (± 8.219)	-1.70 (± 6.037)	-1.50 (± 6.578)
Neu./Leukocytes:CAW4(n=28,27,33,31, 32,25,30,30)	-1.42 (± 8.812)	-0.30 (± 7.754)	-1.52 (± 6.661)	0.06 (± 8.536)

Neu./Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.95 (± 8.648)	-0.58 (± 7.009)	-0.64 (± 6.833)	-1.14 (± 6.872)
Neu./Leuk:CAFvisit(n=30,29,30,32,30,31,32,30)	-1.71 (± 7.046)	-0.65 (± 6.057)	-1.86 (± 6.892)	1.32 (± 7.355)
Bas./Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.06 (± 0.431)	-0.02 (± 0.690)	-0.06 (± 0.524)	0.08 (± 0.319)
Bas/Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.02 (± 0.304)	0.01 (± 0.493)	-0.09 (± 0.342)	0.02 (± 0.323)
Bas./Leukocytes:CAW2(n=28,27,33,31,32,25,30,30)	-0.07 (± 0.485)	0.06 (± 0.651)	-0.03 (± 0.420)	0.01 (± 0.402)
Bas./Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.07 (± 0.272)	0.11 (± 0.809)	-0.12 (± 0.480)	0.08 (± 0.458)
Bas./Leuk.:CAF visit(n=30,29,30,32,30,31,32,30)	-0.04 (± 0.360)	-0.15 (± 0.476)	-0.13 (± 0.443)	0.02 (± 0.512)
Eos./Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.09 (± 1.390)	0.17 (± 1.840)	0.17 (± 0.934)	-0.37 (± 1.549)
Eos./Leukocytes:CAW2(n=34,33,32,34,32,30,33,32)	-0.11 (± 1.801)	-0.20 (± 1.298)	-0.16 (± 1.284)	0.11 (± 1.460)
Eos./Leukocytes:CAW4(n=28,27,33,31,32,25,30,31)	0.42 (± 1.982)	-0.12 (± 1.725)	0.15 (± 1.884)	-0.37 (± 1.729)
Eos./Leukocytes:CAW6(n=29,27,27,31,32,31,24,32,33)	-0.03 (± 1.522)	0.22 (± 1.570)	-0.04 (± 1.213)	0.02 (± 2.126)
Eos./Leuk:CAFvisit(n=30,29,30,32,30,31,32,30)	0.16 (± 1.754)	-0.24 (± 1.860)	-0.09 (± 1.155)	-0.41 (± 2.188)
Mon/Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.02 (± 1.913)	0.12 (± 1.391)	0.50 (± 1.428)	-0.06 (± 1.409)
Mon/Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	0.04 (± 2.055)	-0.31 (± 1.502)	0.30 (± 1.522)	-0.13 (± 1.267)
Mon/Leukocytes:CAW4(n=28,27,33,31,32,25,30,30)	-0.51 (± 2.509)	-0.17 (± 1.966)	-0.02 (± 2.072)	-0.10 (± 1.582)
Mon/Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.06 (± 2.488)	0.33 (± 2.257)	-0.00 (± 1.813)	-0.24 (± 1.217)
Mon/Leuk:CAW visit(n=30,29,30,32,30,31,32,30)	0.06 (± 2.105)	-0.22 (± 1.304)	0.50 (± 1.463)	-0.07 (± 1.226)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	35	34
Units: Percentage of cells				
arithmetic mean (standard deviation)				
Hematocrit: CAW1(n=34,35,32,34,34,33,35,33)	-0.8 (± 2.41)	-0.5 (± 1.97)	-0.9 (± 2.04)	-0.9 (± 2.30)
Hematocrit: CAW2(n=34,33,32,34,32,30,33,30)	-0.7 (± 2.58)	-0.9 (± 2.55)	-0.7 (± 2.24)	-1.0 (± 2.61)
Hematocrit: CAW4(n=28,27,33,31,30,31,25,30)	0.0 (± 2.73)	-1.0 (± 2.34)	-0.9 (± 2.29)	-0.5 (± 2.56)
Hematocrit:CAW6(n=29,27,31,32,31,24,32,33)	-0.6 (± 2.51)	-1.1 (± 1.98)	-1.1 (± 2.84)	-0.8 (± 2.60)
Hematocrit: CAFvisit(n=30,29,30,32,30,31,32,30)	-0.2 (± 2.50)	-0.6 (± 2.20)	-0.6 (± 2.73)	-0.3 (± 2.78)
Reticulocytes/Ery.CAW1(n=31,31,29,29,27,28,31,27)	0.11 (± 0.318)	0.01 (± 0.320)	0.04 (± 0.355)	0.01 (± 0.329)
Reticulocytes/Ery.CAW2(n=31,30,29,29,25,26,29,24)	0.19 (± 0.443)	-0.10 (± 0.318)	0.06 (± 0.315)	-0.01 (± 0.389)
Reticulocytes/Ery.CAW4(n=25,24,30,27,25,23,26,23)	0.10 (± 0.409)	0.03 (± 0.290)	0.04 (± 0.446)	0.05 (± 0.374)

Reticulocytes/Ery.CAW6(n=26,25,28,28,24,22,28,26)	0.15 (± 0.399)	-0.15 (± 0.310)	-0.01 (± 0.355)	0.01 (± 0.463)
Ret./Ery.CAFvisit(n=27,25,27, 27, 23, 27, 27, 23)	-0.03 (± 0.298)	-0.09 (± 0.331)	-0.19 (± 0.395)	0.11 (± 0.448)
Lym./Leuk.CAW1(n=34,35,32,34,3433, 35, 34)	1.31 (± 6.259)	0.59 (± 5.179)	0.49 (± 5.509)	1.79 (± 6.269)
Lym./Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	0.23 (± 6.175)	0.50 (± 5.405)	0.72 (± 6.638)	0.86 (± 7.264)
Lym./Leukocytes:CAW4(n=28,27,33,31,32,25,20,30)	2.41 (± 6.577)	-1.38 (± 5.415)	1.07 (± 5.739)	0.56 (± 7.264)
Lym./Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	1.65 (± 5.818)	0.50 (± 4.452)	-0.04 (± 5.300)	1.52 (± 7.266)
Lym./Leuk.:CAFvisit(n=30,29,30,32,30,31,32,30)	1.34 (± 6.165)	0.22 (± 6.315)	0.07 (± 5.103)	2.48 (± 6.914)
Neu./Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.96 (± 7.843)	-0.17 (± 5.769)	-1.87 (± 6.873)	-1.44 (± 6.580)
Neu./Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.24 (± 6.146)	-0.49 (± 6.665)	-1.04 (± 7.376)	-0.56 (± 8.017)
Neu./Leukocytes:CAW4(n=28,27,33,31,32,25,30,30)	-2.25 (± 7.468)	1.65 (± 6.622)	-1.42 (± 6.498)	-0.45 (± 7.362)
Neu./Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	-1.15 (± 6.969)	-0.56 (± 5.699)	0.13 (± 6.029)	-1.01 (± 8.445)
Neu./Leuk:CAFvisit(n=30,29,30,32,30,31,32,30)	-1.32 (± 6.559)	-0.41 (± 6.961)	-0.71 (± 6.590)	-2.04 (± 7.700)
Bas./Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.03 (± 0.515)	-0.03 (± 0.291)	-0.01 (± 0.411)	-0.01 (± 0.570)
Bas/Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.03 (± 0.532)	0.03 (± 0.355)	-0.06 (± 0.624)	-0.24 (± 0.709)
Bas./Leukocytes:CAW2(n=28,27,33,31,32,25,30,30)	-0.08 (± 0.712)	-0.05 (± 0.362)	-0.01 (± 0.465)	-0.10 (± 0.464)
Bas./Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.16 (± 0.557)	-0.05 (± 0.296)	-0.12 (± 0.576)	-0.17 (± 0.750)
Bas./Leuk.:CAF visit(n=30,29,30,32,30,31,32,30)	-0.25 (± 0.541)	-0.05 (± 0.449)	0.01 (± 0.472)	-0.25 (± 0.572)
Eos./Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.31 (± 1.607)	-0.19 (± 1.410)	0.89 (± 1.850)	-0.23 (± 1.339)
Eos./Leukocytes:CAW2(n=34,33,32,34,32,30,33,32)	-0.27 (± 1.131)	-0.14 (± 1.199)	0.16 (± 1.304)	-0.05 (± 1.531)
Eos./Leukocytes:CAW4(n=28,27,33,31,32,25,30,31)	-0.35 (± 1.431)	-0.34 (± 1.258)	0.40 (± 1.468)	-0.37 (± 1.747)
Eos./Leukocytes:CAW6(n=29,27,27,31,32,31,24,32,33)	-0.15 (± 1.714)	-0.01 (± 1.767)	0.05 (± 1.229)	-0.19 (± 1.840)
Eos./Leuk:CAFvisit(n=30,29,30,32,30,31,32,30)	0.12 (± 1.954)	-0.05 (± 2.805)	0.50 (± 1.986)	-0.13 (± 2.021)
Mon/Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.01 (± 1.593)	-0.19 (± 1.043)	0.51 (± 1.275)	-0.11 (± 1.251)
Mon/Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	0.38 (± 1.362)	0.11 (± 1.318)	0.22 (± 1.414)	-0.01 (± 1.755)
Mon/Leukocytes:CAW4(n=28,27,33,31,32,25,30,30)	0.22 (± 1.323)	0.14 (± 1.323)	-0.03 (± 1.039)	0.33 (± 1.695)
Mon/Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.12 (± 1.030)	0.13 (± 0.807)	-0.02 (± 1.324)	-0.16 (± 1.516)
Mon/Leuk:CAW visit(n=30,29,30,32,30,31,32,30)	0.13 (± 1.205)	0.26 (± 1.543)	0.15 (± 1.599)	-0.04 (± 1.047)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	34
Units: 10^12*cells per litre				
arithmetic mean (standard deviation)				
Erythrocytes: CAW1(n=34,35,32,34,34,33,35,34)	0.03 (± 0.261)	-0.07 (± 0.232)	-0.12 (± 0.264)	-0.04 (± 0.252)
Erythrocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.05 (± 0.234)	-0.03 (± 0.212)	-0.18 (± 0.251)	-0.10 (± 0.208)
Erythrocytes:CAW4(n=28,27,33,31,32,25,30,30)	-0.01 (± 0.216)	-0.05 (± 0.221)	-0.16 (± 0.251)	-0.10 (± 0.233)
Erythrocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.04 (± 0.247)	-0.01 (± 0.180)	-0.17 (± 0.265)	-0.04 (± 0.238)
Erythrocytes:CAW visit(n=30,29,30,32,30,31,32,30)	0.03 (± 0.220)	0.02 (± 0.244)	-0.15 (± 0.266)	-0.03 (± 0.254)
Reticulocytes:CAW1(n=31,31,29,29,27,28,31,27)	0.0 (± 0.02)	0.0 (± 0.02)	-0.0 (± 0.02)	0.0 (± 0.02)
Reticulocytes:CAW2(n=31,30,29,29,25,26,29,24)	-0.0 (± 0.02)	0.0 (± 0.02)	0.0 (± 0.02)	-0.0 (± 0.02)
Reticulocytes:CAW4(n=25,24,30,27,25,23,26,23)	0.0 (± 0.03)	-0.0 (± 0.02)	-0.0 (± 0.02)	0.0 (± 0.02)
Reticulocytes:CAW6(n=26,25,28,28,24,22,28,26)	-0.0 (± 0.02)	0.0 (± 0.02)	0.0 (± 0.02)	-0.0 (± 0.02)
Reticulocytes:CAFvisit(n=27,25,27,27,23,27,27,23)	-0.0 (± 0.02)	-0.0 (± 0.02)	0.0 (± 0.02)	-0.0 (± 0.02)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	35	34
Units: 10^12*cells per litre				
arithmetic mean (standard deviation)				

Erythrocytes: CAW1(n=34,35,32,34,34,33,35,34)	-0.08 (± 0.254)	-0.08 (± 0.298)	-0.08 (± 0.192)	-0.09 (± 0.240)
Erythrocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.07 (± 0.242)	-0.10 (± 0.366)	-0.06 (± 0.229)	-0.11 (± 0.232)
Erythrocytes:CAW4(n=28,27,33,31,32,25,30,30)	0.01 (± 0.275)	-0.12 (± 0.271)	-0.08 (± 0.248)	-0.06 (± 0.219)
Erythrocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.02 (± 0.262)	-0.10 (± 0.256)	-0.07 (± 0.303)	-0.08 (± 0.239)
Erythrocytes:CAW visit(n=30,29,30,32,30,31,32,30)	0.04 (± 0.300)	-0.08 (± 0.280)	-0.03 (± 0.308)	-0.05 (± 0.262)
Reticulocytes:CAW1(n=31,31,29,29,27,28,31,27)	0.0 (± 0.02)	0.0 (± 0.01)	0.0 (± 0.02)	-0.0 (± 0.02)
Reticulocytes:CAW2(n=31,30,29,29,25,26,29,24)	0.0 (± 0.02)	-0.0 (± 0.02)	0.0 (± 0.02)	-0.0 (± 0.02)
Reticulocytes:CAW4(n=25,24,30,27,25,23,26,23)	0.0 (± 0.02)	-0.0 (± 0.01)	-0.0 (± 0.02)	0.0 (± 0.02)
Reticulocytes:CAW6(n=26,25,28,28,24,22,28,26)	0.0 (± 0.02)	-0.0 (± 0.01)	-0.0 (± 0.02)	0.0 (± 0.02)
Reticulocytes:CAFvisit(n=27,25,27,27,23,27,27,23)	-0.0 (± 0.01)	-0.0 (± 0.02)	-0.0 (± 0.02)	0.0 (± 0.02)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point title	Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	35	33	34
Units: 10^9 *cells per litre				
arithmetic mean (standard deviation)				
Platelets:CAW1(n=34,25,32,34,34,33,35,34)	0.9 (± 60.03)	6.8 (± 34.08)	-3.3 (± 32.39)	1.0 (± 25.76)
Platelets:CAW2(n=34,33,32,34,32,30,33,31)	-4.9 (± 58.16)	7.1 (± 43.34)	-8.1 (± 41.92)	-0.1 (± 32.45)

Platelets:CAW4(n=28,27,33,31,32,25,30,30)	10.5 (± 36.42)	10.1 (± 37.55)	-2.4 (± 37.68)	-0.3 (± 36.27)
Platelets:CAW6(n=29,27,31,32,31,24,32,33)	4.9 (± 35.17)	-3.3 (± 32.76)	-6.6 (± 41.66)	-2.3 (± 32.70)
Platelets:CAFvisit(n=29,29,30,32,30,31,32,30)	1.3 (± 30.48)	16.3 (± 37.13)	-8.5 (± 30.15)	0.1 (± 32.36)
Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.027 (± 1.8740)	0.395 (± 1.0940)	-0.051 (± 1.2403)	0.407 (± 1.2225)
Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.206 (± 1.8886)	0.459 (± 1.5567)	-0.288 (± 1.6842)	-0.094 (± 1.2877)
Leukocytes:CAW4(n=28,27,33,31,32,25,30,30)	-0.203 (± 1.7390)	0.729 (± 1.3199)	0.189 (± 1.3534)	0.085 (± 1.3541)
Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.160 (± 1.7059)	0.066 (± 1.0672)	-0.505 (± 1.6474)	0.237 (± 1.4501)
Leukocytes:CAFvisit(n=30,29,30,32,30,31,32,30)	-0.066 (± 1.5744)	0.479 (± 1.0939)	-0.048 (± 2.0206)	0.329 (± 1.3938)
Lymphocytes:CAW1(n=34,35,32,34,34,33,35,34)	-0.008 (± 0.5539)	0.124 (± 0.3659)	0.107 (± 0.3130)	0.081 (± 0.3839)
Lymphocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.061 (± 0.5558)	0.145 (± 0.3735)	0.010 (± 0.4115)	0.044 (± 0.4225)
Lymphocytes:CAW4(n=28,27,33,31,32,25,30,30)	0.107 (± 0.4302)	0.229 (± 0.3998)	0.135 (± 0.4400)	0.012 (± 0.4596)
Lymphocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.033 (± 0.3375)	0.016 (± 0.3437)	-0.079 (± 0.4826)	0.104 (± 0.4337)
LymphocytesCAFvisit(n=30,29,30,32,30,31,32,30)	0.134 (± 0.3256)	0.194 (± 0.3533)	0.065 (± 0.6042)	-0.022 (± 0.4419)
Neutrophils:CAW1(n=34,35,32,34,34,33,35,34)	0.027 (± 1.6137)	0.205 (± 0.9185)	-0.177 (± 1.0805)	0.319 (± 1.0276)
Neutrophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.119 (± 1.5672)	0.293 (± 1.5459)	-0.261 (± 1.3969)	-0.136 (± 1.0669)
Neutrophils:CAW4(n=28,27,33,31,32,25,30,30)	-0.304 (± 1.6117)	0.441 (± 1.2814)	0.036 (± 1.1595)	0.096 (± 1.3199)
Neutrophils:CAW6(n=29,27,31,32,31,24,32,33)	0.112 (± 1.6282)	-0.001 (± 0.8996)	-0.362 (± 1.3154)	0.112 (± 1.2240)
Neutrophils:CAFvisit(n=30,29,30,32,30,31,32,30)	-0.229 (± 1.3379)	0.261 (± 0.8874)	-0.114 (± 1.4545)	0.343 (± 1.3049)
Basophils:CAW1(n=34,35,32,34,34,33,35,34)	-0.006 (± 0.0319)	0.004 (± 0.0445)	-0.007 (± 0.0349)	0.010 (± 0.0258)
Basophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.002 (± 0.0179)	0.004 (± 0.0261)	-0.009 (± 0.0276)	0.001 (± 0.0197)
Basophils:CAW4(n=28,27,33,31,32,25,30,30)	-0.006 (± 0.0328)	0.011 (± 0.0404)	-0.002 (± 0.0300)	0.001 (± 0.0256)
Basophils:CAW6(n=29,27,31,32,31,24,32,33)	-0.005 (± 0.0186)	0.009 (± 0.0489)	-0.012 (± 0.0313)	0.008 (± 0.0344)
Basophils:CAFvisit(n=30,29,30,32,30,31,32,30)	-0.004 (± 0.0265)	-0.003 (± 0.0259)	-0.007 (± 0.0321)	0.007 (± 0.0407)
Eosinophils:CAW1(n=34,35,32,34,34,33,35,34)	0.007 (± 0.0964)	0.036 (± 0.0963)	-0.004 (± 0.1092)	-0.011 (± 0.0930)
Eosinophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.019 (± 0.1087)	-0.000 (± 0.0734)	-0.023 (± 0.0809)	0.009 (± 0.0980)
Eosinophils:CAW4(n=28,27,33,31,32,25,30,30)	0.032 (± 0.1813)	0.018 (± 0.1120)	0.008 (± 0.1325)	-0.019 (± 0.1102)
Eosinophils:CAW6(n=29,27,31,32,31,24,32,33)	0.002 (± 0.0935)	0.029 (± 0.1090)	-0.025 (± 0.1351)	0.018 (± 0.1387)
Eosinophils:CAFvisit(n=30,29,30,32,30,31,32,30)	0.022 (± 0.1461)	0.006 (± 0.0931)	-0.023 (± 0.1196)	-0.004 (± 0.1810)
Monocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.006 (± 0.1796)	0.030 (± 0.0855)	0.030 (± 0.0987)	0.009 (± 0.0879)
Monocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.006 (± 0.1509)	0.016 (± 0.1343)	-0.003 (± 0.0724)	-0.014 (± 0.1055)
Monocytes:CAW4(n=28,27,33,31,32,25,30,30)	-0.035 (± 0.1904)	0.030 (± 0.1212)	0.013 (± 0.1234)	-0.003 (± 0.1092)

Monocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.017 (± 0.1777)	0.017 (± 0.1069)	-0.025 (± 0.1191)	-0.005 (± 0.1021)
Monocytes:CAF visit(n=30,29,30,32,30,31,32,30)	0.011 (± 0.1806)	0.021 (± 0.0824)	0.030 (± 0.1467)	0.005 (± 0.0887)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	33	35	34
Units: 10^9 *cells per litre				
arithmetic mean (standard deviation)				
Platelets:CAW1(n=34,25,32,34,34,33,35,34)	8.5 (± 41.61)	6.6 (± 33.40)	-2.1 (± 31.94)	12.6 (± 44.08)
Platelets:CAW2(n=34,33,32,34,32,30,33,31)	5.0 (± 31.39)	-4.9 (± 31.84)	7.5 (± 37.94)	14.8 (± 50.99)
Platelets:CAW4(n=28,27,33,31,32,25,30,30)	-5.9 (± 37.47)	4.4 (± 37.79)	0.7 (± 36.51)	11.0 (± 46.26)
Platelets:CAW6(n=29,27,31,32,31,24,32,33)	-5.2 (± 38.53)	0.2 (± 37.28)	-1.8 (± 37.05)	8.6 (± 47.85)
Platelets:CAFvisit(n=29,29,30,32,30,31,32,30)	10.2 (± 47.30)	-5.2 (± 40.70)	5.8 (± 48.55)	2.5 (± 58.75)
Leukocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.259 (± 1.1290)	0.068 (± 1.2929)	0.238 (± 1.4993)	-0.025 (± 2.3529)
Leukocytes:CAW2(n=34,33,32,34,32,30,33,31)	-0.116 (± 1.0364)	-0.007 (± 1.2637)	0.422 (± 1.8986)	-0.006 (± 2.3428)
Leukocytes:CAW4(n=28,27,33,31,32,25,30,30)	-0.074 (± 1.0641)	0.398 (± 1.5999)	0.168 (± 1.0902)	0.041 (± 2.1647)
Leukocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.244 (± 1.2763)	-0.269 (± 1.0761)	-0.048 (± 1.3823)	-0.347 (± 2.1442)
Leukocytes:CAFvisit(n=30,29,30,32,30,31,32,30)	0.123 (± 0.8496)	-0.117 (± 1.4856)	0.210 (± 1.7456)	-0.404 (± 2.4817)
Lymphocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.186 (± 0.3840)	0.051 (± 0.3557)	0.089 (± 0.4320)	0.223 (± 0.3849)
Lymphocytes:CAW2(n=34,33,32,34,32,30,33,31)	0.012 (± 0.4251)	-0.003 (± 0.3165)	0.070 (± 0.4603)	0.169 (± 0.5319)
Lymphocytes:CAW4(n=28,27,33,31,32,25,30,30)	0.139 (± 0.3977)	0.039 (± 0.4169)	0.127 (± 0.2630)	0.176 (± 0.6274)
Lymphocytes:CAW6(n=29,27,31,32,31,24,32,33)	0.068 (± 0.3168)	-0.033 (± 0.3092)	0.027 (± 0.2455)	0.079 (± 0.3846)
LymphocytesCAFvisit(n=30,29,30,32,30,31,32,30)	0.130 (± 0.4277)	-0.035 (± 0.4054)	0.050 (± 0.4699)	0.195 (± 0.4663)
Neutrophils:CAW1(n=34,35,32,34,34,33,35,34)	0.069 (± 1.0706)	0.017 (± 1.1291)	0.030 (± 1.3015)	-0.251 (± 2.2421)
Neutrophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.109 (± 0.9653)	-0.015 (± 1.1305)	0.288 (± 1.7822)	-0.190 (± 2.0749)
Neutrophils:CAW4(n=28,27,33,31,32,25,30,30)	-0.190 (± 1.0404)	0.338 (± 1.3577)	-0.005 (± 0.9958)	-0.158 (± 2.0005)
Neutrophils:CAW6(n=29,27,31,32,31,24,32,33)	-0.250 (± 1.1720)	-0.228 (± 0.9681)	-0.064 (± 1.2422)	-0.376 (± 2.1125)
Neutrophils:CAFvisit(n=30,29,30,32,30,31,32,30)	-0.020 (± 0.7731)	-0.093 (± 1.2340)	0.088 (± 1.4614)	-0.562 (± 2.3227)
Basophils:CAW1(n=34,35,32,34,34,33,35,34)	0.003 (± 0.0361)	0.001 (± 0.0191)	0.002 (± 0.0299)	0.002 (± 0.0343)
Basophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.005 (± 0.0394)	0.003 (± 0.0244)	-0.003 (± 0.0433)	-0.012 (± 0.0428)
Basophils:CAW4(n=28,27,33,31,32,25,30,30)	-0.007 (± 0.0495)	-0.001 (± 0.0255)	-0.001 (± 0.0337)	-0.004 (± 0.0323)

Basophils:CAW6(n=29,27,31,32,31,24,32,33)	-0.015 (± 0.0415)	-0.004 (± 0.0188)	-0.009 (± 0.0373)	-0.015 (± 0.0383)
Basophils:CAFvisit(n=30,29,30,32,30,31,32,30)	-0.015 (± 0.0426)	-0.005 (± 0.0269)	0.001 (± 0.0295)	-0.019 (± 0.0361)
Eosinophils:CAW1(n=34,35,32,34,34,33,35,34)	-0.014 (± 0.1216)	-0.008 (± 0.1148)	0.068 (± 0.0959)	-0.006 (± 0.1165)
Eosinophils:CAW2(n=34,33,32,34,32,30,33,31)	-0.029 (± 0.0915)	-0.006 (± 0.0621)	0.022 (± 0.0762)	0.005 (± 0.1256)
Eosinophils:CAW4(n=28,27,33,31,32,25,30,30)	-0.032 (± 0.1040)	-0.012 (± 0.0832)	0.042 (± 0.1076)	-0.012 (± 0.1499)
Eosinophils:CAW6(n=29,27,31,32,31,24,32,33)	-0.027 (± 0.1125)	-0.007 (± 0.1025)	-0.001 (± 0.0812)	-0.022 (± 0.1415)
Eosinophils:CAFvisit(n=30,29,30,32,30,31,32,30)	0.008 (± 0.1270)	-0.008 (± 0.2483)	0.048 (± 0.1520)	-0.011 (± 0.1945)
Monocytes:CAW1(n=34,35,32,34,34,33,35,34)	0.019 (± 0.1055)	0.006 (± 0.0877)	0.051 (± 0.1244)	0.011 (± 0.1195)
Monocytes:CAW2(n=34,33,32,34,32,30,33,31)	0.017 (± 0.0865)	0.013 (± 0.0983)	0.049 (± 0.1471)	0.025 (± 0.1496)
Monocytes:CAW4(n=28,27,33,31,32,25,30,30)	0.009 (± 0.0986)	0.035 (± 0.0978)	0.007 (± 0.1008)	0.038 (± 0.1331)
Monocytes:CAW6(n=29,27,31,32,31,24,32,33)	-0.019 (± 0.0726)	0.004 (± 0.0847)	0.003 (± 0.1097)	-0.012 (± 0.1200)
Monocytes:CAF visit(n=30,29,30,32,30,31,32,30)	0.021 (± 0.0739)	0.018 (± 0.1047)	0.029 (± 0.1788)	-0.006 (± 0.1282)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Lipids Profile Values at Week 6

End point title	Change From Baseline in Lipids Profile Values at Week 6

End point description:

Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point and "n" signifies subjects evaluable for the each specified rows.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	27	31	32
Units: Microgram per decilitre				
arithmetic mean (standard deviation)				
HDL cholesterol	-2.8 (± 6.65)	0.1 (± 5.34)	-1.3 (± 7.74)	2.7 (± 8.33)
Triglycerides(n=28,27,31,31,29,24,30,32)	3.3 (± 38.84)	-4.2 (± 59.30)	-6.5 (± 37.30)	1.8 (± 60.74)
Cholesterol	-3.5 (± 16.39)	-5.6 (± 27.59)	-12.8 (± 20.53)	6.8 (± 24.09)

LDL Cholesterol	-3.4 (± 14.45)	-6.3 (± 25.28)	-12.1 (± 16.44)	2.1 (± 20.13)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	24	30	32
Units: Microgram per decilitre				
arithmetic mean (standard deviation)				
HDL cholesterol	1.9 (± 11.18)	0.0 (± 6.76)	1.2 (± 4.12)	0.3 (± 8.56)
Triglycerides(n=28,27,31,31,29,24,30,32)	-18.9 (± 56.78)	-8.1 (± 50.41)	-7.0 (± 58.36)	-4.4 (± 55.66)
Cholesterol	-10.4 (± 30.79)	-0.2 (± 18.70)	5.3 (± 30.58)	-0.9 (± 19.86)
LDL Cholesterol	-11.0 (± 29.06)	-0.8 (± 14.48)	4.4 (± 23.55)	-1.1 (± 16.29)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6

End point title	Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6

End point description:

Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "Number of Subjects Analysed" signifies subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Baseline, Week 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	27	31	32
Units: Ratio				
arithmetic mean (standard deviation)	0.0 (± 0.31)	-0.1 (± 0.48)	-0.2 (± 0.40)	-0.0 (± 0.32)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	24	30	32
Units: Ratio				
arithmetic mean (standard deviation)	-0.3 (± 0.77)	-0.0 (± 0.35)	0.0 (± 0.46)	-0.0 (± 0.42)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6

End point title	Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Beats per minute				
arithmetic mean (standard deviation)				
Baseline	66.8 (± 11.45)	66.9 (± 9.33)	68.4 (± 14.66)	64.9 (± 9.05)
Change at week 2 (n=33,31,33,33,31,26,34,32)	0.7 (± 10.05)	-0.5 (± 8.03)	-1.8 (± 11.53)	-0.6 (± 7.88)
Change at week 6(n=28,27,33,32,30,24,31,33)	0.3 (± 6.19)	-1.1 (± 7.65)	-1.7 (± 9.06)	0.8 (± 8.53)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Beats per minute				
arithmetic mean (standard deviation)				
Baseline	64.9 (± 12.26)	66.9 (± 12.03)	68.2 (± 12.11)	68.1 (± 12.48)
Change at week 2 (n=33,31,33,33,31,26,34,32)	1.9 (± 8.01)	2.2 (± 8.76)	1.7 (± 9.13)	1.7 (± 12.52)
Change at week 6(n=28,27,33,32,30,24,31,33)	-0.3 (± 8.46)	-0.8 (± 8.23)	0.5 (± 8.76)	-0.4 (± 12.06)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6

End point title	Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Milliseconds				
arithmetic mean (standard deviation)				
PR interval: baseline	161.9 (± 23.30)	160.2 (± 24.01)	161.4 (± 27.59)	162.5 (± 22.04)
PR interval:CAW2(n=33,31,33,33,31,26,34	0.8 (± 14.41)	-0.9 (± 15.92)	0.7 (± 18.54)	0.3 (± 10.13)
PR interval:CAW 6(n=28,27,33,32,30,24,31,33)	-0.9 (± 10.16)	-0.1 (± 13.81)	2.8 (± 19.66)	2.9 (± 13.63)
QRS interval: baseline	92.5 (± 9.36)	91.5 (± 9.71)	91.1 (± 9.29)	93.0 (± 11.13)
QRS intervalCAW2(n=33,31,33,33,31,26,34,	-1.4 (± 8.02)	-0.4 (± 5.34)	-1.3 (± 3.46)	-0.8 (± 5.64)
QRS interval:CAW6(n=28,27,33,32,30,24,31	-1.9 (± 6.55)	1.4 (± 5.62)	-0.5 (± 4.76)	-0.9 (± 4.04)
QTCF interval: baseline	407.7 (± 17.78)	397.9 (± 15.98)	403.8 (± 22.43)	408.5 (± 18.42)
QTCF interval:CAW 2(n=33,31,33,33,31,26,34,32)	-5.7 (± 11.86)	-1.5 (± 13.70)	-3.9 (± 15.60)	2.6 (± 16.20)
QTCF interval:CAW6(n=28,27,33,32,30,24,31	-4.1 (± 14.61)	-0.5 (± 14.93)	-1.9 (± 14.37)	0.3 (± 17.19)
QT interval: baseline	395.2 (± 31.53)	385.3 (± 23.64)	388.8 (± 33.66)	401.0 (± 25.23)
QT interval:CAW 2(n=33,31,33,33,31,26,34,32)	-5.9 (± 23.16)	-1.3 (± 17.73)	-1.1 (± 19.31)	3.5 (± 21.06)
QT interval:CAW6(n=28,27,33,32,30,24,31	-4.9 (± 19.54)	1.3 (± 18.11)	0.9 (± 16.11)	-4.1 (± 23.42)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Milliseconds				
arithmetic mean (standard deviation)				
PR interval: baseline	160.7 (± 24.20)	156.4 (± 22.65)	157.9 (± 23.55)	157.8 (± 23.15)
PR interval:CAW2(n=33,31,33,33,31,26,34	1.1 (± 14.42)	6.0 (± 14.79)	1.2 (± 16.06)	2.1 (± 7.98)
PR interval:CAW 6(n=28,27,33,32,30,24,31,33)	3.5 (± 21.88)	4.0 (± 14.56)	6.5 (± 19.15)	5.7 (± 16.11)
QRS interval: baseline	93.1 (± 8.69)	92.2 (± 13.00)	92.4 (± 13.30)	91.5 (± 11.68)
QRS intervalCAW2(n=33,31,33,33,31,26,34,	0.1 (± 4.79)	1.5 (± 9.29)	0.2 (± 8.07)	1.0 (± 5.63)
QRS interval:CAW6(n=28,27,33,32,30,24,31	-1.3 (± 4.00)	0.9 (± 6.37)	0.6 (± 5.49)	0.7 (± 5.67)
QTCF interval: baseline	401.0 (± 16.29)	403.0 (± 16.65)	397.7 (± 17.05)	405.0 (± 20.38)
QTCF interval:CAW 2(n=33,31,33,33,31,26,34,32)	-0.6 (± 12.75)	1.4 (± 15.56)	2.4 (± 10.32)	-4.6 (± 15.43)
QTCF interval:CAW6(n=28,27,33,32,30,24,31	-1.4 (± 14.93)	4.6 (± 14.27)	2.0 (± 11.94)	-0.2 (± 9.67)
QT interval: baseline	392.0 (± 27.36)	390.9 (± 24.87)	383.8 (± 30.79)	390.6 (± 32.43)
QT interval:CAW 2(n=33,31,33,33,31,26,34,32)	-4.5 (± 15.75)	1.2 (± 24.03)	-2.3 (± 18.69)	-4.6 (± 25.76)
QT interval:CAW6(n=28,27,33,32,30,24,31	-0.9 (± 20.12)	7.8 (± 24.11)	-1.4 (± 20.47)	4.0 (± 27.74)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6

End point title	Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6

End point description:

Blood pressure included supine and sitting systolic and diastolic BP. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	29	22
Units: Millimeters of mercury				
arithmetic mean (standard deviation)				
Supine systolic BP: Baseline	123.3 (± 12.01)	123.2 (± 12.35)	123.0 (± 13.89)	119.7 (± 9.08)
Supine SBP:CAW2(n=21,20,25,18,20,18,21,22)	0.3 (± 11.55)	-1.4 (± 9.61)	0.5 (± 14.73)	2.3 (± 6.99)
Supine SBP:CAW 6(n=16,15,24,17,19,18,21,22)	-0.2 (± 12.98)	1.1 (± 10.06)	2.0 (± 14.05)	0.2 (± 9.13)
Sitting SBP: Baseline(n=15,17,17,19,19,16,18,15)	117.7 (± 13.05)	120.8 (± 10.26)	120.2 (± 12.43)	116.9 (± 17.76)
Sitting SBP: CAW2(n=12,11,8,15,11,7,11,10)	1.3 (± 12.12)	-1.9 (± 11.86)	-3.9 (± 14.54)	1.3 (± 13.59)
Sitting SBP: CAW6(n=12,10,9,15,10,5,10,11)	0.6 (± 12.24)	-7.5 (± 8.67)	-9.4 (± 8.95)	1.0 (± 14.63)
Supine DBP: Baseline	77.7 (± 9.28)	75.2 (± 8.79)	78.8 (± 8.39)	74.5 (± 8.26)
Supine DBP: CAW2(n=21,20,25,18,20,18,21,22)	0.5 (± 7.51)	0.6 (± 6.47)	-0.4 (± 8.50)	1.6 (± 10.33)
Supine DBP: CAW 6(n=16,15,24,17,19,18,21,22)	-2.5 (± 7.69)	1.5 (± 7.61)	-0.7 (± 8.32)	0.5 (± 7.96)
Sitting DBP: Baseline	76.5 (± 9.28)	80.1 (± 6.76)	77.8 (± 10.02)	69.6 (± 11.48)
Sitting DBP: CAW2(n=12, 11, 8, 15, 11, 7, 11, 10)	-1.6 (± 8.49)	0.7 (± 7.93)	0.0 (± 9.44)	1.6 (± 12.00)
Sitting DBP: CAW 6(n=12, 10, 9, 15, 10, 5, 10, 11)	0.8 (± 9.90)	0.0 (± 5.79)	-1.6 (± 11.97)	1.1 (± 15.61)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	26	23	25
Units: Millimeters of mercury				
arithmetic mean (standard deviation)				
Supine systolic BP: Baseline	122.6 (± 12.76)	123.1 (± 12.40)	117.1 (± 14.07)	118.9 (± 12.43)
Supine SBP:CAW2(n=21,20,25,18,20,18,21,22)	-0.3 (± 10.25)	-0.3 (± 8.02)	3.5 (± 13.65)	2.9 (± 8.48)
Supine SBP:CAW 6(n=16,15,24,17,19,18,21,22)	-3.4 (± 11.02)	-1.4 (± 10.49)	2.1 (± 12.41)	0.6 (± 10.31)
Sitting SBP: Baseline(n=15,17,17,19,19,16,18,15)	124.6 (± 11.25)	119.4 (± 12.96)	122.9 (± 15.25)	125.6 (± 12.21)
Sitting SBP: CAW2(n=12,11,8,15,11,7,11,10)	-2.4 (± 11.76)	-3.1 (± 10.46)	1.1 (± 9.81)	4.4 (± 11.68)
Sitting SBP: CAW6(n=12,10,9,15,10,5,10,11)	-8.4 (± 10.81)	-0.6 (± 14.40)	-3.6 (± 8.37)	-1.5 (± 5.80)
Supine DBP: Baseline	75.9 (± 8.78)	77.5 (± 8.71)	74.4 (± 8.20)	73.7 (± 8.59)
Supine DBP: CAW2(n=21,20,25,18,20,18,21,22)	1.2 (± 8.32)	-2.8 (± 6.69)	1.6 (± 8.89)	1.4 (± 7.74)
Supine DBP: CAW 6(n=16,15,24,17,19,18,21,22)	-0.9 (± 10.65)	-1.6 (± 6.22)	1.9 (± 9.72)	0.5 (± 6.32)
Sitting DBP: Baseline	80.9 (± 8.21)	75.1 (± 5.77)	77.1 (± 12.00)	80.3 (± 7.83)
Sitting DBP: CAW2(n=12, 11, 8, 15, 11, 7, 11, 10)	-2.9 (± 10.77)	1.7 (± 8.20)	4.5 (± 5.80)	-1.2 (± 6.49)

Sitting DBP: CAW 6(n=12, 10, 9, 15, 10, 5, 10, 11)	-5.3 (± 9.27)	-2.8 (± 12.60)	-0.3 (± 7.89)	0.4 (± 8.41)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6

End point title	Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Beats per minute				
arithmetic mean (standard deviation)				
Baseline	69.6 (± 12.58)	69.5 (± 9.82)	72.9 (± 14.30)	67.9 (± 9.31)
Change at week 2(n=33,31,33,33,31,26,33,32)	0.5 (± 10.41)	0.2 (± 8.11)	-2.5 (± 9.66)	1.1 (± 9.13)
Change at week 6(n=28,27,33,32,30,24,31,33)	2.1 (± 10.59)	0.3 (± 8.04)	-1.4 (± 11.90)	0.9 (± 9.71)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Beats per minute				
arithmetic mean (standard deviation)				
Baseline	68.8 (± 11.76)	69.4 (± 11.15)	70.1 (± 11.18)	68.2 (± 9.59)
Change at week 2(n=33,31,33,33,31,26,33,32)	0.5 (± 6.54)	3.7 (± 9.47)	2.8 (± 8.28)	4.1 (± 9.16)
Change at week 6(n=28,27,33,32,30,24,31,33)	1.8 (± 8.73)	4.1 (± 6.76)	0.5 (± 9.12)	1.8 (± 8.64)

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6

End point title	Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6

End point description:

Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "n" signifies subjects evaluable for the each specified time point.

End point type	Secondary

End point timeframe:

Baseline, Weeks 2 and 6

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	37	36	37
Units: Degree Celsius				
arithmetic mean (standard deviation)				
Baseline	36.5 (± 0.33)	36.5 (± 0.43)	36.6 (± 0.44)	36.6 (± 0.33)
Change at week 2(n=33,31,33,33,31,26,33,32)	-0.1 (± 0.41)	-0.1 (± 0.30)	0.0 (± 0.38)	-0.0 (± 0.43)
Change at week 6(n=28,27,33,32,30,24,31,33)	-0.0 (± 0.40)	-0.0 (± 0.29)	0.0 (± 0.38)	0.1 (± 0.32)

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	36	36	37
Units: Degree Celsius				
arithmetic mean (standard deviation)				
Baseline	36.5 (± 0.37)	36.5 (± 0.29)	36.6 (± 0.41)	36.6 (± 0.29)
Change at week 2(n=33,31,33,33,31,26,33,32)	0.1 (± 0.35)	-0.0 (± 0.34)	0.0 (± 0.38)	0.0 (± 0.41)
Change at week 6(n=28,27,33,32,30,24,31,33)	0.0 (± 0.29)	0.1 (± 0.50)	0.0 (± 0.37)	-0.0 (± 0.46)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Each Severity Grade in Local Tolerability Assessments

End point title	Number of Subjects With Each Severity Grade in Local

	Tolerability Assessments

End point description:

Local tolerability skin assessments were performed by investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent [if still in place]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent [if still in place]). Higher grades indicated worsening of condition. Only those categories in which at least 1 subject had data were reported. Safety analysis set included all subjects who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, "N" signifies number of subjects evaluable for this end point.

End point type	Secondary

End point timeframe:

Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)

End point values	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD	PF-06700841 1.0% Cream QD
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	36	31	33
Units: Subjects				
Day 1: tolerability before: none	35	35	31	33
Day 1: tolerability before: mild	0	0	1	3
Day 1: tolerability before: moderate	2	2	4	1
Day 1: tolerability after: none	33	36	30	33
Day 1: tolerability after: mild	1	0	1	2
Day 1: tolerability after: moderate	1	1	3	1
Week 1: tolerability before: none	31	28	28	30
Week 1: tolerability before: mild	1	2	3	3
Week 1: tolerability before: moderate	2	0	3	0
Week 1: tolerability after: none	28	29	29	30
Week 1: tolerability after: mild	2	2	2	3
Week 1: tolerability after: moderate	2	0	2	0
Week 2: tolerability before: none	29	28	26	30
Week 2: tolerability before: mild	3	2	2	2
Week 2: tolerability before: moderate	1	0	3	1
Week 2: tolerability after: none	28	26	29	31
Week 2: tolerability after: mild	1	3	2	1
Week 2: tolerability after: moderate	1	0	1	1
Week 4: tolerability before: none	27	26	30	30
Week 4: tolerability before: mild	0	2	2	2
Week 4: tolerability before: moderate	1	0	1	0
Week 4: tolerability after: none	24	26	30	30
Week 4: tolerability after: mild	1	2	2	1
Week 4: tolerability after: moderate	1	0	0	0
Week 6: tolerability before: none	26	25	29	30
Week 6: tolerability before: mild	1	1	2	1
Week 6: tolerability after: none	25	24	28	29
Week 6: tolerability after: mild	0	1	3	0

Early termination: tolerability: none	6	5	3	2
Early termination: tolerability: mild	0	2	0	0
Early termination:tolerability: moderate	2	0	0	0
Early termination:tolerability: severe	1	1	0	1
Follow Up: tolerability: none	22	26	25	25
Follow Up: tolerability: mild	1	0	2	0
Follow Up: tolerability: moderate	1	0	1	4
Follow Up: tolerability: severe	0	0	1	0

End point values	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	36	35	34	36
Units: Subjects				
Day 1: tolerability before: none	36	35	34	36
Day 1: tolerability before: mild	0	1	2	0
Day 1: tolerability before: moderate	0	0	0	1
Day 1: tolerability after: none	35	34	32	33
Day 1: tolerability after: mild	0	0	2	2
Day 1: tolerability after: moderate	0	1	0	0
Week 1: tolerability before: none	30	30	33	33
Week 1: tolerability before: mild	3	1	1	1
Week 1: tolerability before: moderate	0	0	0	0
Week 1: tolerability after: none	28	27	32	31
Week 1: tolerability after: mild	2	3	1	1
Week 1: tolerability after: moderate	0	1	0	0
Week 2: tolerability before: none	30	23	31	33
Week 2: tolerability before: mild	1	1	1	0
Week 2: tolerability before: moderate	0	0	1	0
Week 2: tolerability after: none	29	23	32	30
Week 2: tolerability after: mild	1	2	0	1
Week 2: tolerability after: moderate	0	0	1	0
Week 4: tolerability before: none	30	24	31	31
Week 4: tolerability before: mild	0	0	1	1
Week 4: tolerability before: moderate	1	1	0	0
Week 4: tolerability after: none	29	24	31	30
Week 4: tolerability after: mild	0	0	1	0
Week 4: tolerability after: moderate	1	1	0	0
Week 6: tolerability before: none	30	21	30	32
Week 6: tolerability before: mild	0	1	0	1
Week 6: tolerability after: none	29	22	30	30
Week 6: tolerability after: mild	0	0	0	0
Early termination: tolerability: none	2	9	2	1
Early termination: tolerability: mild	0	0	0	1
Early termination:tolerability: moderate	0	1	0	0
Early termination:tolerability: severe	1	0	0	0
Follow Up: tolerability: none	28	25	26	28
Follow Up: tolerability: mild	0	1	1	1
Follow Up: tolerability: moderate	1	1	0	0

Follow Up: tolerability: severe	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	Vehicle Cream Once Daily (QD)

Reporting group description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.1% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.1 percent (%) cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 0.3 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 1.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 3.0% Cream QD

Reporting group description:

Subjects or caregivers of subjects, topically applied of PF-06700841 3.0 % cream on all eligible AD areas (of subjects) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	Vehicle Cream Twice Daily (BID)

Reporting group description:

Subjects or caregivers of subjects, topically applied vehicle cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 0.3% Cream BID

Reporting group description:

Subjects or caregivers of subjects, topically applied PF-06700841 0.3% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Reporting group title	PF-06700841 1.0% Cream BID

Reporting group description:

Subjects or caregivers of subjects, topically applied PF-06700841 1.0% cream on all eligible AD areas (of subjects) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Subjects were followed up for 4 weeks after last dose.

Serious adverse events	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Vehicle Cream Once Daily (QD)	PF-06700841 0.1% Cream QD	PF-06700841 0.3% Cream QD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 37 (48.65%)	17 / 37 (45.95%)	11 / 36 (30.56%)
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Application site erythema			

subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Application site pruritus			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Administration site warmth			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Application site acne			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Application site pain			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Injection site pain			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Oedema peripheral			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Pain			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	1	0	1
Pyrexia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0

Cockroach allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Mite allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Allergy to animal			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Metrorrhagia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	0	2
Oropharyngeal pain			
subjects affected / exposed	1 / 37 (2.70%)	2 / 37 (5.41%)	1 / 36 (2.78%)
occurrences (all)	1	2	1
Increased viscosity of bronchial secretion			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Aspartate aminotransferase increased			

subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	1 / 36 (2.78%)
occurrences (all)	0	1	1
Blood glucose increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Glomerular filtration rate decreased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Lipids abnormal			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Neutrophil count decreased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Pregnancy test positive			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	1 / 37 (2.70%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	1	1	0
Tooth fracture			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Burning sensation			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Swelling of eyelid			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Ulcerative keratitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	3 / 37 (8.11%)	3 / 37 (8.11%)	1 / 36 (2.78%)
occurrences (all)	3	3	1
Pruritus			
subjects affected / exposed	2 / 37 (5.41%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	3	1	0
Acne			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Dermatitis contact			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Eczema			

subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	1 / 37 (2.70%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	1	1	0
Granuloma annulare			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Skin irritation			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Solar urticaria			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Neck pain			

subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Influenza			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	1 / 37 (2.70%)	2 / 37 (5.41%)	2 / 36 (5.56%)
occurrences (all)	1	2	2
Urinary tract infection			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	2 / 36 (5.56%)
occurrences (all)	2	0	2
Bacterial allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Eczema infected			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1

Gastroenteritis viral			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Gingivitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Herpes simplex			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Kaposi's varicelliform eruption			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Laryngitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Staphylococcal skin infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 37 (0.00%)	1 / 37 (2.70%)	1 / 36 (2.78%)
occurrences (all)	0	1	1

Vaginal infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Viral pharyngitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 37 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Viral rhinitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 37 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1

Non-serious adverse events	PF-06700841 1.0% Cream QD	PF-06700841 3.0% Cream QD	Vehicle Cream Twice Daily (BID)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 37 (32.43%)	10 / 36 (27.78%)	17 / 36 (47.22%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Application site erythema			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	2 / 36 (5.56%)
occurrences (all)	0	0	2
Application site pruritus			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	3 / 36 (8.33%)
occurrences (all)	0	0	3
Administration site warmth			

subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Application site acne			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Application site pain			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	1 / 36 (2.78%)
occurrences (all)	0	1	1
Chills			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Injection site pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	1 / 36 (2.78%)
occurrences (all)	0	1	1
Vessel puncture site haematoma			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Cockroach allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Mite allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1

Allergy to animal			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Metrorrhagia			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Increased viscosity of bronchial secretion			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			

subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Blood glucose increased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram T wave inversion			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Glomerular filtration rate decreased			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Lipids abnormal			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Pregnancy test positive			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Burning sensation			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Eye disorders			

Swelling of eyelid			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Ulcerative keratitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Dyspepsia			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	3 / 36 (8.33%)
occurrences (all)	0	1	3
Pruritus			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	1 / 37 (2.70%)	1 / 36 (2.78%)	1 / 36 (2.78%)
occurrences (all)	1	1	1
Dry skin			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Granuloma annulare			

subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Skin irritation			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Solar urticaria			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 37 (5.41%)	1 / 36 (2.78%)	0 / 36 (0.00%)
occurrences (all)	2	1	0
Nasopharyngitis			

subjects affected / exposed	3 / 37 (8.11%)	4 / 36 (11.11%)	2 / 36 (5.56%)
occurrences (all)	3	4	3
Urinary tract infection			
subjects affected / exposed	2 / 37 (5.41%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	2	0	0
Bacterial allergy			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Eczema infected			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	2
Furuncle			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Herpes simplex			

subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Kaposi's varicelliform eruption			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	1	0	1
Rhinitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Staphylococcal skin infection			
subjects affected / exposed	0 / 37 (0.00%)	1 / 36 (2.78%)	0 / 36 (0.00%)
occurrences (all)	0	1	0
Tonsillitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Vaginal infection			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Viral pharyngitis			

subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Viral rhinitis			
subjects affected / exposed	0 / 37 (0.00%)	0 / 36 (0.00%)	0 / 36 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 37 (2.70%)	0 / 36 (0.00%)	1 / 36 (2.78%)
occurrences (all)	1	0	1

Non-serious adverse events	PF-06700841 0.3% Cream BID	PF-06700841 1.0% Cream BID	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 36 (25.00%)	14 / 37 (37.84%)	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Application site erythema			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Application site pruritus			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Administration site warmth			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Application site acne			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Application site pain			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	

Chills			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Injection site pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Pyrexia			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Vessel puncture site haematoma			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Immune system disorders			
Allergy to arthropod sting			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Cockroach allergy			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Mite allergy			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Allergy to animal			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Metrorrhagia			

subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Oropharyngeal pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Increased viscosity of bronchial secretion			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Blood bilirubin increased			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Blood glucose increased			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Electrocardiogram T wave inversion			

subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Glomerular filtration rate decreased			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Lipids abnormal			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Neutrophil count decreased			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Pregnancy test positive			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Injury, poisoning and procedural complications			
Limb injury			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Tooth fracture			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Nervous system disorders			
Burning sensation			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Headache			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Swelling of eyelid			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Ulcerative keratitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			

Dyspepsia			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Nausea			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	0 / 36 (0.00%)	2 / 37 (5.41%)	
occurrences (all)	0	2	
Pruritus			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Acne			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Dermatitis contact			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Dry skin			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Eczema			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	1 / 36 (2.78%)	1 / 37 (2.70%)	
occurrences (all)	1	1	
Granuloma annulare			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Hyperhidrosis			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Photosensitivity reaction			

subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Skin discolouration			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Skin irritation			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Solar urticaria			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Neck pain			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Influenza			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	2 / 36 (5.56%)	2 / 37 (5.41%)	
occurrences (all)	2	2	
Urinary tract infection			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Bacterial allergy			

subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Bronchitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Conjunctivitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Cystitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Eczema infected			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Folliculitis			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Furuncle			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Gastroenteritis viral			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Gingivitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Herpes simplex			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Kaposi's varicelliform eruption			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Laryngitis			

subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Oral herpes			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Pharyngitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Skin infection			
subjects affected / exposed	1 / 36 (2.78%)	0 / 37 (0.00%)	
occurrences (all)	1	0	
Staphylococcal skin infection			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Tonsillitis			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Upper respiratory tract infection			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Vaginal infection			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Viral infection			
subjects affected / exposed	0 / 36 (0.00%)	1 / 37 (2.70%)	
occurrences (all)	0	1	
Viral pharyngitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Viral rhinitis			
subjects affected / exposed	0 / 36 (0.00%)	0 / 37 (0.00%)	
occurrences (all)	0	0	
Viral upper respiratory tract infection			

subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0	0 / 37 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported